<SEC-DOCUMENT>0001213900-20-020895.txt : 20200807
<SEC-HEADER>0001213900-20-020895.hdr.sgml : 20200807
<ACCEPTANCE-DATETIME>20200807160226
ACCESSION NUMBER:		0001213900-20-020895
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20200807
DATE AS OF CHANGE:		20200807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-242322
		FILM NUMBER:		201085235

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ea125182-s3_actiniumpharma.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange
Commission on August 7, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES </B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C.
20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Form
S-3</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACTINIUM PHARMACEUTICALS,
INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant
as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>275 Madison Avenue,
7th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10016
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(646) 677-3870</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address, including
zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Sandesh Seth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chairman and Chief
Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Actinium Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>275 Madison Avenue,
7th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10016
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(646) 677-3870</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address, including
zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>With Copies to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rick A. Werner,
Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Jayun Koo, Esq.</B><BR>
<B>Haynes and Boone, LLP</B><BR>
<B>30 Rockefeller Plaza, 26</B><SUP>th</SUP> <B>Floor</B><BR>
<B>New York, New York 10112</B><BR>
<B>Tel. (212) 659-7300</B><BR>
<B>Fax (212) 884-8234</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Approximate date of commencement of
proposed sale to the public:</B> From time to time after the effective date of this registration statement, as determined by market
conditions and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If the only securities being registered
on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest reinvestment plans, check the following box. &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule 413(b) under the Securities Act, check the following box. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 56%; text-align: center"><FONT STYLE="font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Smaller reporting company &#9746;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Emerging growth company &#9744;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CALCULATION OF
REGISTRATION FEE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold">Title of each class of securities to be registered</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount <BR>
to be <BR>
Registered (1)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed <BR>
Maximum<BR> Aggregate
    <BR>
Offering&nbsp;Price <BR>
Per Security (2)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed <BR>
Maximum<BR> Aggregate
    <BR>
Offering&nbsp;<BR>
Price (3)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount&nbsp;of <BR>
Registration&nbsp;<BR>
Fee</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%">Common stock, $0.001 par value per share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Preferred stock, $0.001 par value per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Subscription rights</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">441,484,981.38</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">441,484,981.38</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">57,304.75</TD><TD STYLE="padding-bottom: 4pt; text-align: left">(3)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">There are being registered hereunder such indeterminate number of
    shares of common stock and preferred stock, such indeterminate number of warrants to purchase common stock or preferred stock,
    such indeterminate number of subscription rights, and such indeterminate number of units as shall have an aggregate initial
    offering price not to exceed $500,000,000. Any securities registered hereunder may be sold separately or as units with the
    other securities registered hereunder. The proposed maximum offering price per unit will be determined, from time to time,
    by the registrant in connection with the issuance by the registrant of the securities registered hereunder. The securities
    registered hereunder also include such indeterminate number of shares of common stock and preferred stock as may be issued
    upon conversion of or exchange for preferred stock that provide for conversion or exchange, upon exercise of warrants or pursuant
    to the antidilution provisions of any of such securities. In addition, pursuant to Rule 416 under the Securities Act, the
    shares being registered hereunder include such indeterminate number of shares of common stock and preferred stock as may be
    issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions.
    </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The proposed maximum offering price per security will be determined
    from time to time by the registrant in connection with, and at the time of, the issuance of the securities and is not specified
    as to each class of security pursuant to General Instruction II.D. of Form S-3, as amended.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Pursuant to Rule 457(o) under the Securities Act, which permits
    the registration fee to be calculated on the basis of the maximum offering price of all the securities listed, and Instruction
    II.C. of Form F-3, the table does not specify by each class information as to the amount to be registered, proposed maximum
    offering price per unit or proposed maximum aggregate offering price.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Rule 415(a)(6) under the Securities Act
        of 1933, as amended (the &ldquo;Securities Act&rdquo;), the securities registered hereunder include unsold securities
        previously registered by the registrant pursuant to the registration statement on Form S-3, Registration No. 333-216748
        (the &ldquo;Prior Shelf Registration Statement&rdquo;), which was declared effective on October 12, 2017, that have not
        yet been sold. The Prior Registration Statement registered the offer and sale of the registrant&rsquo;s common stock,
        preferred stock, debt securities, warrants, rights, purchase contracts, and/or units having an aggregate initial offering
        price not to exceed $200,000,000, $58,515,018.62 of which securities remain unsold by the registrant as of the date of
        filing of this registration statement. To the extent that, after the filing date hereof and prior to the effectiveness
        of this registration statement, the registrant sells any unsold securities pursuant to the Prior Registration Statement,
        the registrant will identify in a pre-effective amendment to this registration statement the updated amount of unsold
        securities from the Prior Registration Statement to be included in this registration statement pursuant to Rule 415(a)(6).
        Pursuant to Rule 415(a)(6), the offering of the unsold securities under the Prior Registration Statement will be deemed
        terminated as of the date of effectiveness of this registration statement. The filing fee of $6,782.18 relating to the
        unsold securities under the Prior Registration Statement, which was paid under the Prior Registration Statement, will
        continue to be applied to the unsold securities registered pursuant to this registration statement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>The Registrant hereby amends
        this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
        shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
        in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective
        on such date as the Commission, acting pursuant to said Section 8(a), may determine.</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Registration Statement contains two prospectuses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a base prospectus which covers the offering, issuance and sale by
    us of up to $500,000,000 of our common stock, preferred stock, warrants, units and/or subscription rights; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a sales agreement prospectus covering the offering, issuance and
    sale by us of up to a maximum aggregate offering price of $200,000,000 of our common stock that may be issued and sold under
    the Capital on Demand&trade; Sales Agreement with JonesTrading Institutional Services LLC.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The base prospectus immediately follows this explanatory note.
The specific terms of any securities to be offered pursuant to the base prospectus other than the shares under the sales agreement
will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold
under the sales agreement are specified in the sales agreement prospectus that immediately follows the base prospectus. The $200,000,000
of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $500,000,000 of securities
that may be offered, issued and sold by us under the base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Red"><B>The
information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell
these securities until the Registration Statement filed with the Securities and Exchange Commission, of which this prospectus
is a part, is effective. This prospectus is not an offer to sell these securities and the selling stockholders named in this prospectus
are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Red"><B>SUBJECT
TO COMPLETION, DATED <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">August 7, 2020</FONT></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Actinium Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$500,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Subscription Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer and sell from time to time, in one or more series
or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this
prospectus, up to an aggregate amount of $500,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will provide specific terms of any offering in a supplement
to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should
carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be
incorporated by reference in this prospectus before you purchase any of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These securities may be offered and sold in the same offering
or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters,
dealers, or agents involved in the sale of our securities, their compensation and any over-allotment options held by them will
be described in the applicable prospectus supplement. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NYSE American under the symbol
&ldquo;ATNM.&rdquo; On August 6, 2020, the last reported sale price of our common stock was $0.428 per share. We recommend that
you obtain current market quotations for our common stock prior to making an investment decision. We will provide information
in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>You should carefully read this prospectus, any prospectus
supplement relating to any specific offering of securities, and all information incorporated by reference herein and therein.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk.
These risks are discussed in this prospectus under &ldquo;Risk Factors&rdquo; beginning on page 5 and in the documents incorporated
by reference into this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 90%; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">ii</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">5</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_004"><FONT STYLE="font-size: 10pt">SPECIAL NOTE REGARDING
    FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">7</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_006"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL
    STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">8</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">10</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">11</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SUBSCRIPTION
    RIGHTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">12</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_010"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">13</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_011"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_012"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_013"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND
    MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#act_014"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN
    INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">16</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="act_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a registration statement on Form
S-3 that we filed with the Securities and Exchange Commission using a &ldquo;shelf&rdquo; registration process. Under this shelf
process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings
up to a total amount of $500,000,000. The offer and sale of securities under this prospectus may be made from time to time, in
one or more offerings, in any manner described under the section in this prospectus entitled &ldquo;Plan of Distribution.&rdquo;
This shelf registration statement is not being filed by us in connection with any presently contemplated securities offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus provides you with a general description of
the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific
information about the terms of that offering. The prospectus supplement may also add to, update or change information contained
in the prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by the information
in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The prospectus supplement to be attached to the front of this
prospectus may describe, as applicable: the terms of the securities offered; the public offering price; the price paid for the
securities; net proceeds; and the other specific terms related to the offering of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should only rely on the information contained or incorporated
by reference in this prospectus and any prospectus supplement or issuer free writing prospectus relating to a particular offering.
No person has been authorized to give any information or make any representations in connection with this offering other than
those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related issuer
free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information
or representations must not be relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement
nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered
securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus
does not contain all of the information included in the registration statement. For a more complete understanding of the offering
of the securities, you should refer to the registration statement, including its exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read the entire prospectus and any prospectus supplement
and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any
prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery
of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under
any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or
issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such prospectus supplement or issuer
free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus supplement
or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time
of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects
may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: center"><A NAME="act_002"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><I>This summary provides an overview of selected information
contained elsewhere or incorporated by reference in this prospectus and does not contain all of the information you should consider
before investing in our securities. You should carefully read the prospectus, the information incorporated by reference and the
registration statement of which this prospectus is a part in their entirety before investing in our securities, including the
information discussed under &ldquo;Risk Factors&rdquo; in this prospectus and the documents incorporated by reference and our
financial statements and notes thereto that are incorporated by reference in this prospectus. As used in this prospectus, unless
the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo; or &ldquo;the Company&rdquo;
refer to Actinium Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries taken as a whole.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>The Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Actinium Pharmaceuticals, Inc. is a clinical-stage,
biopharmaceutical company applying its proprietary platform technology and deep understanding of radioimmunobiology to the development
of novel targeted therapies known as ARCs or Antibody Radiation-Conjugates. Radiation is an effective therapeutic modality that
is used in the treatment of over fifty percent of all cancer patients and often combined with chemotherapy and immunotherapy for
greater therapeutic effect. Radiation is typically administered from outside the body, which constrains the amount that can be
administered to patients due to dose-limiting toxicities. In addition, due to the diffuse nature of the external radiation beam,
its usage is limited to solid tumors and cannot be used in blood cancers, which are diffuse. ARCs combine the cell-killing ability
of a radioisotope payload with a targeting agent, such as a monoclonal antibody, or mAb, to deliver radiation inside the body
to specific cells, to potentially generate greater efficacy and less toxicity. ARCs usage is broader than external delivered radiation
as they can be used for both solid tumors and blood cancers. Blood or hematologic cancers are highly sensitive to radiation and
our clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic
cancers. Our clinical programs are focused on two primary areas: targeted conditioning prior to a cell or gene therapy procedure
and therapeutics, either in combination with other agents or as a monotherapy. Our product development strategy is actively informed
by clinical data with our ARCs in over 500 patients, including the ongoing SIERRA trial. Our clinical pipeline has emanated from
our AWE, or Antibody Warhead Enabling technology platform, which is protected by over 120 issued and pending patents, trade secrets
and know-how and is being utilized in a collaborative research partnership with Astellas Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We are advancing the only multi-target,
multi-indication clinical-stage pipeline for targeted conditioning and the only ARC-based targeted conditioning regimens in development.
Our ARCs for targeted conditioning are intended to potentially enable improved access to cell-based therapies with curative potential,
including BMT, or bone marrow transplant, ACT, or adoptive cell therapy such as CAR-T, and Gene Therapy, as well as improved outcomes.
Conditioning in the context of BMT, ACT or Gene Therapy is the act of depleting certain blood and immune-forming cells, including
bone marrow stem cells and, in some cases, diseased cells prior to transplanting new cells into a patient. Currently, conditioning
is accomplished using a combination of chemotherapeutic agents and external radiation. These non-targeted conditioning regimens
may prevent a patient from receiving a potentially curative therapy and hinder outcomes due to their toxicities. ARCs have the
potential to increase patient access and outcomes by way of their ability to selectively deplete targeted cells while sparing
normal healthy cells. We use our ARCs at high isotope dose levels to achieve myeloablation, which fully depletes bone marrow stem
cells and at lower isotope dose levels to achieve lymphodepletion, which spares bone marrow stem cells from depletion. In addition,
dosing may be titrated downward from myeloablative doses to achieve partial myeloablation, which may be appropriate for certain
gene therapy programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Impact of COVID&ndash;19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">In December 2019,
a novel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China
to other countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo;
or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and closed non-essential businesses, and as of the date of this
prospectus, many local jurisdictions continue to have such restrictions in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As many local jurisdictions
continue to have such restrictions in place, our ability to continue to operate our business may also be limited. Such events
may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which
could materially affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote
working and thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical development
of our drug candidates. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but
there is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. Therefore, the
COVID-19 pandemic may continue to affect our operation, may further divert the attention and efforts of the medical community
to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The spread of COVID-19, which has caused
a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration
of, the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted, including new
information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among
others, the pandemic has resulted significant disruptions in the general commercial activity and the global economy and caused
financial market volatility and uncertainty in significant and unforeseen ways in the recent months. A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access
capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from
the spread of COVID-19 could materially affect our business and the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, the Phase 3 SIERRA trial for
our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with investigators providing
feedback that recruitment and enrollment will remain active because of the acute nature of the disease, the high unmet needs of
patients with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated profile of Iomab-B. Certain
sites that had not been actively enrolling due to COVID-19 have resumed recruitment and enrollment. We also believe our earlier
stage clinical trials for our CD33 program will also continue to recruit and enroll patients given the acute nature of relapsed
or refractory AML. The continuation of the pandemic could adversely affect our planned clinical trial operations, including our
ability to conduct the trials on the expected timelines and recruit and retain patients and principal investigators and site staff
who, as healthcare providers, may have heightened exposure to COVID-19 if their geography is impacted by the pandemic. Further,
the continuation and/or resurgence of the COVID-19 pandemic could result in delays in our clinical trials due to prioritization
of hospital resources toward the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials at
this time, or the inability of patients to comply with clinical trial protocols if quarantines or travel restrictions impede patient
movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations
and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies
and clinical trials, and the pandemic may affect their ability to devote sufficient time and resources to our programs or to travel
to sites to perform work for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, COVID-19 may result in delays
in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&rsquo;s or Institutional
Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, COVID-19 has not had a financial
impact on our company. However, COVID-19 has caused severe disruptions in transportation and limited access to our facility, resulting
in limited support from our staff and professional advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ultimate impact from COVID-19 on our
business operations and financial results during 2020 will depend on, among other things, the ultimate severity and scope of the
pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease,
the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with
which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results
during 2020 and beyond, but developments related to COVID-19 may materially affect us in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Corporate and Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">We were organized as a corporation in the State of
Nevada in October 1997 and reorganized as a corporation in the State of Delaware in March 2013. Our principal executive offices
are located at 275 Madison Avenue, 7th Floor, New York, New York 10016. Our telephone number is (646) 677-3870. Our website address
is www.actiniumpharma.com. Information accessed through our website is not incorporated into this prospectus and is not a part
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>The Securities We May Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">We may offer up to $500,000,000 of common stock, preferred
stock, warrants, units and/or subscription rights in one or more offerings and in any combination. This prospectus provides you
with a general description of the securities we may offer. A prospectus supplement, which we will provide each time we offer securities,
will describe the specific amounts, prices and terms of these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">We may issue shares of our common stock from time to
time. The holders of our common stock are entitled to one vote per share. Our certificate of incorporation does not provide for
cumulative voting. Our directors are divided into three classes. At each annual meeting of stockholders, directors elected to
succeed those directors whose terms expire are elected for a term of office to expire at the third succeeding annual meeting of
stockholders after their election. The holders of our common stock are entitled to receive ratably such dividends, if any, as
may be declared by our board of directors out of legally available funds; however, the current policy of our board of directors
is to retain earnings, if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common
stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock
have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common
stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may
be designated solely by action of our board of directors and issued in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Our common stock is listed on the NYSE American under
the symbol &ldquo;ATNM.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">We may issue shares of our preferred stock from time
to time, in one or more series. Our board of directors will determine the rights, preferences, stated values, qualifications or
limitations, without any further vote or action by stockholders. Convertible preferred stock will be convertible into our common
stock or exchangeable for our other securities. Conversion may be mandatory or at your option or both and would be at prescribed
conversion rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">If we sell any series of preferred stock under this
prospectus and applicable prospectus supplements, we will fix the rights, preferences, privileges and restrictions of the preferred
stock of such series in the certificate of designation relating to that series. We will file as an exhibit to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the Securities and
Exchange Commission, the form of any certificate of designation that describes the terms of the series of preferred stock we are
offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement
related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms
of the applicable series of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">We may issue warrants for the purchase of common stock
or preferred stock in one or more series. We may issue warrants independently or together with common stock or preferred stock,
and the warrants may be attached to or separate from these securities. We will evidence each series of warrants by warrant certificates
that we will issue under a separate agreement. We may enter into warrant agreements with a bank or trust company that we select
to be our warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating
to a particular series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">In this prospectus, we have summarized certain general
features of the warrants. We urge you, however, to read the applicable prospectus supplement related to the particular series
of warrants being offered, as well as the warrant agreements and warrant certificates that contain the terms of the warrants.
We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from
reports that we file with the Securities and Exchange Commission, the form of warrant agreement or warrant certificate containing
the terms of the warrants we are offering before the issuance of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">We may issue units consisting of common stock, preferred
stock and/or warrants for the purchase of common stock or preferred stock in one or more series. In this prospectus, we have summarized
certain general features of the units. We urge you, however, to read the applicable prospectus supplement related to the series
of units being offered, as well as the unit agreements that contain the terms of the units. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference reports that we file with the Securities and Exchange
Commission, the form of unit agreement and any supplemental agreements that describe the terms of the series of units we are offering
before the issuance of the related series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Subscription Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue subscription rights to purchase shares of common
stock or other securities. These subscription rights may be issued independently or together with any other security offered hereby
and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection with any
offering of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant
to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such
offering. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference
reports that we file with the Securities and Exchange Commission, the form of such agreement and any supplemental agreements that
describe the terms of the subscription rights we are offering before the issuance of such subscription rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_003"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An investment in our securities involves a high degree of risk.
The prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to an
investment in our securities. Before deciding whether to invest in our securities, you should carefully consider the specific
factors discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement, together with all of the
other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference
in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item&nbsp;1A, &ldquo;Risk
Factors,&rdquo; in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2019, which is incorporated herein
by reference, as updated or superseded by the risks and uncertainties described under similar headings in the other documents
that are filed after the date hereof and incorporated by reference into this prospectus and any prospectus supplement related
to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also affect our operations. Past financial performance may
not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in
future periods. If any of these risks actually occurs, our business, business prospects, financial condition or results of operations
could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part
of your investment. Please also read carefully the section below entitled &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_004"></A><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus, each prospectus supplement and the information
incorporated by reference in this prospectus and each prospectus supplement contain &ldquo;forward-looking statements,&rdquo;
which include information relating to future events, future financial performance, strategies, expectations, competitive environment
and regulation. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future
tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance
or results and will probably not be accurate indications of when such performance or results will be achieved. Forward-looking
statements are based on information we have when those statements are made or our management&rsquo;s good faith belief as of that
time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results
to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause
such differences include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our history of recurring losses and negative cash flows from operating
    activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete
    business objectives;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to complete clinical trials as anticipated and obtain and
    maintain regulatory approvals for our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to adequately protect our intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">disputes over ownership of intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our dependence on a single manufacturing facility and our ability to
    comply with stringent manufacturing quality standards and to increase production as necessary;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the risk that the data collected from our current and planned clinical
    trials may not be sufficient to demonstrate that our products are an attractive alternative to other procedures and products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">intense competition in our industry, with competitors having substantially
    greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution
    and personnel resources than we do;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">entry of new competitors and products and potential technological obsolescence
    of our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">loss of a key customer or supplier;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">adverse economic conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">adverse federal, state and local government regulation, in the United
    States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">price increases for supplies and components;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">inability to carry out research, development and commercialization plans;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">loss or retirement of key executives and research scientists; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to regain and maintain compliance with the continued listing requirements of
    the NYSE American and the risk that our common stock will be delisted if we cannot do so;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the geographic, social and economic impact of COVID-19 on the Company&rsquo;s business and
    liquidity; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">other factors discussed in this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should review carefully the section entitled &ldquo;Risk
Factors&rdquo; beginning on page 5 of this prospectus for a discussion of these and other risks that relate to our business
and investing in our securities. The forward-looking statements contained or incorporated by reference in this prospectus or any
prospectus supplement are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation
to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement
is made or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_005"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we specify another use in the applicable prospectus
supplement, we will use the net proceeds from the sale of the securities offered by us for general corporate purposes, which may
include, among other things, debt repayment, working capital and/or capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may also use such proceeds to fund acquisitions of product
candidates or technologies that complement our current business. We may set forth additional information on the use of net proceeds
from the sale of the securities we offer under this prospectus in a prospectus supplement related to a specific offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors are cautioned, however, that expenditures may vary
substantially from these uses. Investors will be relying on the judgment of our management, who will have broad discretion regarding
the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous
factors, including the amount of cash generated by our operations, the amount of competition and other operational factors. We
may find it necessary or advisable to use portions of the proceeds from this offering for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we evaluate these and other factors and
we anticipate continuing to make such evaluations to determine if the existing allocation of resources, including the proceeds
of this offering, is being optimized. Circumstances that may give rise to a change in the use of proceeds include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">a change in development plan or strategy; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">delays or difficulties with our clinical trials; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">negative results from our clinical trials; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">difficulty obtaining regulatory approval; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">failure to achieve sales as anticipated; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the addition of new product candidates or technologies; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">our ability to negotiate definitive agreement with acquisition
    candidates; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the availability and terms of debt financing to fund a portion
    of the purchase price(s) for potential acquisitions; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the availability of other sources of cash including cash flow
    from operations and new bank debt financing arrangements, if any. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pending other uses, we intend to invest the proceeds to us
in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed
obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds invested will yield a favorable, or
any, return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_006"></A><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description of common stock and preferred stock
summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus,
but is not complete. For the complete terms of our common stock and preferred stock, please refer to our certificate of incorporation,
as amended and our amended and restated bylaws, as may be amended from time to time. While the terms we have summarized below
will apply generally to any future common stock or preferred stock that we may offer, we will describe the specific terms of any
series of preferred stock in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement,
the terms of any preferred stock we offer under that prospectus supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have authorized 1,050,000,000 shares of capital stock, par
value $0.001 per share, of which 1,000,000,000 are shares of common stock and 50,000,000 are shares of preferred stock. On August
5, 2020, there were 407,558,060 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.
The authorized and unissued shares of common stock and the authorized and undesignated shares of preferred stock are available
for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any
stock exchange on which our securities may be listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also have warrants that are outstanding, which are described
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of our common stock are entitled to one vote per
share. Our Certificate of Incorporation does not provide for cumulative voting. Our directors are divided into three classes.
At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire are elected for a term
of office to expire at the third succeeding annual meeting of stockholders after their election. The holders of our common stock
are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available
funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets
that are legally available for distribution. There are no preemptive, subscription, conversion rights, redemption or sinking fund
provisions regarding the common stock. The rights, preferences and privileges of holders of our common stock are subject to, and
may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action
of our board of directors and issued in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transfer agent and registrar for our common stock is Action
Stock Transfer Corporation. The transfer agent&rsquo;s address is 2469 East Fort Union Blvd., Suite 214, Salt Lake City, UT 84121.
Our common stock is listed on the NYSE American under the symbol &ldquo;ATNM.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The board of directors is authorized, subject to any limitations
prescribed by law, without further vote or action by the stockholders, to issue from time to time up to 50,000,000 shares of preferred
stock in one or more series. Each such series of preferred stock shall have such number of shares, designations, preferences,
voting powers, qualifications, and special or relative rights or privileges as shall be determined by the board of directors,
which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights.
Issuance of preferred stock by our board of directors may result in such shares having dividend and/or liquidation preferences
senior to the rights of the holders of our common stock and could dilute the voting rights of the holders of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Prior to the issuance of shares of each
series of preferred stock, the board of directors is required by the Delaware General Corporation Law and our Certificate of Incorporation
to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware. The certificate
of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions,
including, but not limited to, some or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">the number of shares constituting that series and the distinctive
    designation of that series, which number may be increased or decreased (but not below the number of shares then outstanding)
    from time to time by action of the board of directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">the dividend rate and the manner and frequency of payment of
    dividends on the shares of that series, whether dividends will be cumulative, and, if so, from which date;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">whether that series will have voting rights, in addition to
    any voting rights provided by law, and, if so, the terms of such voting rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">whether that series will have conversion privileges, and, if
    so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events
    as the board of directors may determine;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">whether or not the shares of that series will be redeemable,
    and, if so, the terms and conditions of such redemption;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">whether that series will have a sinking fund for the redemption
    or purchase of shares of that series, and, if so, the terms and amount of such sinking fund;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">whether or not the shares of the series will have priority over
    or be on a parity with or be junior to the shares of any other series or class in any respect;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">the rights of the shares of that series in the event of voluntary
    or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights or priority, if any, of
    payment of shares of that series; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">any other relative rights, preferences and limitations of that
    series.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Once designated by our board of directors,
each series of preferred stock may have specific financial and other terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Anti-Takeover Law and Provisions of
Our Certificate of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Provisions of our Certificate of Incorporation
and Bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management,
including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders
might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common
stock. Among other things, our Certificate of Incorporation and Bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">permits our board of directors to issue up to 50,000,000 shares of preferred stock, without further action by the stockholders, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors in office;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">divide our board of directors into three classes, with each class serving staggered three-year terms;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">provide that special meetings of our stockholders may be called only by our board of directors, chairman or chief executive officer; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">provide advance notice provisions with which a stockholder who wishes to nominate a director or propose other business to be considered at a stockholder meeting must comply.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_007"></A><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of August 5, 2020, there were 55,435,898 shares of common
stock that may be issued upon exercise of outstanding pre-funded warrants and 86,070,575 shares of common stock that may be issued
upon exercise of other outstanding warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue warrants for the purchase of common stock or preferred
stock in one or more series. We may issue warrants independently or together with common stock or preferred stock, and the warrants
may be attached to or separate from these securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will evidence each series of warrants by warrant certificates
that we may issue under a separate agreement. We may enter into a warrant agreement with a warrant agent. Each warrant agent may
be a bank or transfer agent that we select which has its principal office in the United States. We may also choose to act as our
own warrant agent. We will indicate the name and address of any such warrant agent in the applicable prospectus supplement relating
to a particular series of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the
terms of the series of warrants, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the offering price and aggregate number of warrants offered;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">if applicable, the designation and terms of the securities with
    which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">if applicable, the date on and after which the warrants and
    the related securities will be separately transferable; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">in the case of warrants to purchase common stock or preferred
    stock, the number or amount of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise
    of one warrant and the price at which and currency in which these shares may be purchased upon such exercise; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the manner of exercise of the warrants, including any cashless
    exercise rights; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the warrant agreement under which the warrants will be issued;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the effect of any merger, consolidation, sale or other disposition
    of our business on the warrant agreement and the warrants; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">anti-dilution provisions of the warrants, if any; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the terms of any rights to redeem or call the warrants; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any provisions for changes to or adjustments in the exercise
    price or number of securities issuable upon exercise of the warrants; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the dates on which the right to exercise the warrants will commence
    and expire or, if the warrants are not continuously exercisable during that period, the specific date or dates on which the
    warrants will be exercisable; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the manner in which the warrant agreement and warrants may be
    modified; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the identities of the warrant agent and any calculation or other
    agent for the warrants; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">federal income tax consequences of holding or exercising the
    warrants; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the terms of the securities issuable upon exercise of the warrants;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any securities exchange or quotation system on which the warrants
    or any securities deliverable upon exercise of the warrants may be listed or quoted; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any other specific terms, preferences, rights or limitations
    of or restrictions on the warrants. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before exercising their warrants, holders of warrants will
not have any of the rights of holders of the securities purchasable upon such exercise, including, in the case of warrants to
purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution
or winding up or to exercise voting rights, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant will entitle the holder to purchase the securities
that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement.
Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any
time up to 5:00 P.M. eastern time, the close of business, on the expiration date that we set forth in the applicable prospectus
supplement. After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of the warrants may exercise the warrants by delivering
the warrant certificate representing the warrants to be exercised together with specified information, and paying the required
exercise price by the methods provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant
certificate, and in the applicable prospectus supplement, the information that the holder of the warrant will be required to deliver
to the warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon receipt of the required payment and the warrant certificate
properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable
prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants
represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights By Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any warrant agent will act solely as our agent under the applicable
warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single
bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility
in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate
any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related
warrant agent or the holder of any other warrant, enforce by appropriate legal action the holder&rsquo;s right to exercise, and
receive the securities purchasable upon exercise of, its warrants in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrant Agreement Will Not Be Qualified Under Trust Indenture
Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No warrant agreement will be qualified as an indenture, and
no warrant agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore, holders of warrants issued
under a warrant agreement will not have the protection of the Trust Indenture Act with respect to their warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant agreement and any warrants issued under the warrant
agreements will be governed by New York law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_008"></A><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units comprised of one or more of the other securities
described in this prospectus or any prospectus supplement in any combination. Each unit will be issued so that the holder of the
unit is also the holder, with the rights and obligations of a holder, of each security included in the unit. The unit agreement
under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at
any time or at any times before a specified date or upon the occurrence of a specified event or occurrence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The applicable prospectus supplement will describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the designation and the terms of the units and of the securities
    comprising the units, including whether and under what circumstances those securities may be held or transferred separately;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any unit agreement under which the units will be issued; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any provisions for the issuance, payment, settlement, transfer
    or exchange of the units or of the securities comprising the units; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">whether the units will be issued in fully registered or global
    form. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_009"></A><B>DESCRIPTION OF SUBSCRIPTION RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a general description of the terms of the
subscription rights we may issue from time to time. Particular terms of any subscription rights we offer will be described in
the prospectus supplement relating to such subscription rights, and may differ from the terms described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue subscription rights to purchase shares of common
stock or other securities offered hereby. These subscription rights may be issued independently or together with any other security
offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection
with any offering of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers
pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after
such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The applicable prospectus supplement will describe the specific
terms of any offering of subscription rights for which this prospectus is being delivered, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">whether common stock or other securities will be offered under the stockholder
    subscription rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the price, if any, for the subscription rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the exercise price payable for each security upon the exercise of the subscription rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the number of subscription rights issued to each stockholder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the number and terms of the securities which may be purchased per each subscription right;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the extent to which the subscription rights are transferable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any other terms of the subscription rights, including the terms, procedures and limitations
    relating to the exchange and exercise of the subscription rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the date on which the right to exercise the subscription rights shall commence, and the
    date on which the subscription rights shall expire;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the extent to which the subscription rights may include an over-subscription privilege with
    respect to unsubscribed securities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">if appropriate, a discussion of material U.S. federal income tax considerations; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">if applicable, the material terms of any standby underwriting or purchase arrangement entered
    into by us in connection with the offering of subscription rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The description in the applicable prospectus supplement of
any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference to the applicable
subscription rights certificate or subscription rights agreement, which will be filed with the Securities and Exchange Commission
if we offer subscription rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_010"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities being offered pursuant to this prospectus
to or through underwriters, through dealers, through agents, or directly to one or more purchasers or through a combination of
these methods. The applicable prospectus supplement will describe the terms of the offering of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the name or names of any underwriters, if any, and if required,
    any dealers or agents; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">the purchase price of the securities and the proceeds we will
    receive from the sale; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any underwriting discounts and other items constituting underwriters&rsquo;
    compensation; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any discounts or concessions allowed or reallowed or paid to
    dealers; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any securities exchange or market on which the securities may
    be listed or traded. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may distribute the securities from time to time in one or
more transactions at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">a fixed price or prices, which may be changed; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">market prices prevailing at the time of sale, directly by us
    or through a designated agent; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">prices related to such prevailing market prices; or </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">negotiated prices. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Only underwriters named in the prospectus supplement are underwriters
of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If underwriters are used in an offering, we will execute an
underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including
any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement.
The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly
by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s)
will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will
be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering
price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. Unless otherwise
set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject
to conditions precedent, and the underwriters will be obligated to purchase all of the offered securities, if any are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may grant to the underwriters options to purchase additional
securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts,
as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus
supplement for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we use a dealer in the sale of the securities being offered
pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. The names
of the dealers and the terms of the transaction will be specified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities directly or through agents we designate
from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions
we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a
best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may authorize agents or underwriters to solicit offers by
institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant
to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of the securities, underwriters,
dealers or agents may receive compensation from us or from purchasers of the securities for whom they act as agents, in the form
of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for
whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any
institutional investors or others that purchase securities directly for the purpose of resale or distribution, may be deemed to
be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the common stock by
them may be deemed to be underwriting discounts and commissions under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may provide agents, underwriters and other purchasers with
indemnification against particular civil liabilities, including liabilities under the Securities Act of 1933, as amended, or contribution
with respect to payments that the agents, underwriters or other purchasers may make with respect to such liabilities. Agents and
underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the public offering of a series of securities,
persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price
of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons participating
in the offering of more securities than have been sold to them by us. In addition, those persons may stabilize or maintain the
price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling
concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them
are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain
the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions,
if commenced, may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any
effect that the transactions described above, if implemented, may have on the price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise specified in the applicable prospectus supplement,
any common stock sold pursuant to a prospectus supplement will be eligible for listing on the NYSE American, subject to official
notice of issuance. Any underwriters to whom securities are sold by us for public offering and sale may make a market in the securities,
but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to comply with the securities laws of some states,
if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed
brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_011"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the securities offered by this prospectus will
be passed upon by Haynes and Boone, LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_012"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements incorporated in this prospectus by
reference to the Annual Report on Form 10-K for the fiscal years ended December&nbsp;31, 2019 and 2018 have been so incorporated
in reliance on the report of Marcum LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_013"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to the informational requirements of the Securities
Exchange Act of 1934, as amended, and in accordance therewith file annual, quarterly and current reports, proxy statements and
other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains a website that
contains such reports, proxy and information statements and other information regarding registrants that file electronically with
the Securities and Exchange Commission. The address of the Securities and Exchange Commission&rsquo;s website is www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We make available free of charge on or through our website
at www.actiniumpharma.com, our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K
and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have filed with the Securities and Exchange Commission a
registration statement under the Securities Act of 1933, as amended, relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus
does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement,
at prescribed rates, from the Securities and Exchange Commission at the address listed above, or for free at www.sec.gov. The
registration statement and the documents referred to below under &ldquo;Incorporation of Certain Information By Reference&rdquo;
are also available on our website, www.actiniumpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not incorporated by reference into this prospectus
the information on our website, and you should not consider it to be a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="act_014"></A><B>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities and Exchange Commission allows us to &ldquo;incorporate
by reference&rdquo; the information we have filed with it, which means that we can disclose important information to you by referring
you to those documents. The information we incorporate by reference is an important part of this prospectus, and later information
that we file with the Securities and Exchange Commission will automatically update and supersede this information. We incorporate
by reference the documents listed below and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01
of Form 8-K) we file with the Securities and Exchange Commission pursuant to Sections l3(a), l3(c), 14 or l5(d) of the Securities
Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior to the termination of the offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/f10k2019_actiniumpharma.htm">Form 10-K</A> for the fiscal year ended December
    31, 2019, filed with the Securities and Exchange Commission on May 8, 2020, and as subsequently amended on Form 10-K/A filed
    with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015102/f10k2019a1_actiniumpharma.htm">June 16, 2020</A> and on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020017370/f10k2019a2_actiniumpharma.htm">July 13, 2020</A>; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020016168/f10q0320_actiniumpharma.htm">Form 10-Q</A> for the quarterly period ended
    March 31, 2020, filed with the Securities and Exchange Commission on June 29, 2020;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Our Current Reports on Forms 8-K filed with the
    Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020007702/ea119813-8k_actiniumpharma.htm">March 27, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020010060/ea120946-8k_actiniumpharma.htm">April 24, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011048/ea121215-8k_actiniumpharma.htm">May 5, 2020</A> (<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342-8k_actinium.htm">two reports</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020012670/ea121138-8k_actinium.htm">May 15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121-8k_actiniumpharma.htm">June 16, 2020</A>
    (<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015114/ea123040-8k_actiniumpharma.htm">two reports</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189-8k_actiniumpharma.htm">June 18, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015376/ea123229-8k_actinium.htm">June 19, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020018562/ea124522-8k_actiniumpharm.htm">July 24, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020020390/ea125058-8k_actinium.htm">August 5, 2020</A>; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The description of the Company&rsquo;s common stock and warrants
    contained in the <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014001685/f8a12b0314_actnium.htm">Form 8-A</A> filed with the Securities and Exchange Commission on March 24, 2014, including any amendments thereto
    or reports filed for the purposes of updating this description. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All filings filed by us pursuant to the Securities Exchange
Act of 1934, as amended, after the date of the initial filing of this registration statement and prior to the effectiveness of
such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall also be deemed
to be incorporated by reference into the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information incorporated by reference
or provided in this prospectus. We have not authorized anyone else to provide you with different information. Any statement contained
in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for the purposes of this
prospectus to the extent that a later statement contained in this prospectus or in any other document incorporated by reference
into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed,
except as so modified or superseded, to constitute a part of this prospectus. You should not assume that the information in this
prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will provide without charge to each person to whom a copy
of this prospectus is delivered, upon written or oral request, a copy of any or all of the reports or documents that have been
incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings, unless
we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to us at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Steve O&rsquo;Loughlin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">275 Madison Avenue, 7th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(646) 677-3870</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may also access the documents incorporated by reference
in this prospectus through our website at www.actiniumpharma.com. Except for the specific incorporated documents listed above,
no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement
of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
<P STYLE="text-align: center; font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>$500,000,000
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_01.jpg" ALT="img_02" STYLE="height: 149px; width: 624px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Subscription
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #DE1A1E"><B>The information in this prospectus is not
complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #DE1A1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #DE1A1E"><B>SUBJECT TO COMPLETION,
DATED AUGUST 7, 2020</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_01.jpg" ALT="img_02" STYLE="height: 149px; width: 624px"></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Actinium
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Up
to $200,000,000 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into a Capital on Demand&trade; Sales Agreement,
or the sales agreement, with JonesTrading Institutional Services LLC, or JonesTrading, dated August 7, 2020, relating to the sale
of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $200,000,000 from time to
time through JonesTrading, acting as agent or principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales of our common stock, if any, under this prospectus will
be made by any method permitted that is deemed an &ldquo;at the market&rdquo; offering as defined in Rule 415 under the Securities
Act of 1933, as amended, or the Securities Act. JonesTrading will act as our sales agent using commercially reasonable efforts
consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or
similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JonesTrading will be entitled to compensation at a
commission rate of 3.0% of the gross sales price per share sold under the sales agreement. See &ldquo;Plan of
Distribution&rdquo; beginning on page 9 for additional information regarding the compensation to be paid to JonesTrading. In
connection with the sale of the shares of common stock on our behalf, JonesTrading will be deemed to be an
&ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the compensation of JonesTrading will be deemed to be
underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to JonesTrading with
respect to certain liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of
risk. These risks are discussed in this prospectus under &ldquo;Risk Factors&rdquo; beginning on page 4 and in the documents
incorporated by reference into this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NYSE American under the symbol
&ldquo;ATNM.&rdquo; On August 6, 2020, the last reported sale price of our common stock was $0.428 per share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_02.jpg" ALT="LOGO" STYLE="height: 41px; width: 138px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020.
&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; text-indent: -10pt; padding-left: 10pt">PROSPECTUS</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 91%; text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_001">ABOUT THIS PROSPECTUS</A></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center">ii</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_002">PROSPECTUS SUMMARY</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_003">RISK FACTORS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_004">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#b_005">USE OF PROCEEDS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#b_006">DILUTION</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#b_007">DIVIDENDS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#b_008">PLAN OF DISTRIBUTION</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_009">LEGAL MATTERS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#b_010">EXPERTS</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_011">WHERE YOU CAN FIND MORE INFORMATION</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><A HREF="#b_012">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="b_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a registration statement on Form
S-3 that we filed with the Securities and Exchange Commission using a &ldquo;shelf&rdquo; registration process. This prospectus
relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully
read this prospectus, together with the information incorporated by reference as described under the heading &ldquo;Where You Can
Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo; These documents contain important
information that you should consider when making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus describes the specific terms of the common stock
we are offering and also adds to and updates information contained in the documents incorporated by reference into this prospectus.
To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained
in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus.
If any statement in one of these documents is inconsistent with a statement in another document having a later date&mdash;for example,
a document incorporated by reference into this prospectus&mdash;the statement in the document having the later date modifies or
supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should only rely on the information contained or incorporated
by reference in this prospectus and any issuer free writing prospectus that we may authorize for use in connection with this offering.
No person has been authorized to give any information or make any representations in connection with this offering other than those
contained or incorporated by reference in this prospectus and any related issuer free writing prospectus in connection with the
offering described herein and therein, and, if given or made, such information or representations must not be relied upon as having
been authorized by us. Neither this prospectus nor any related issuer free writing prospectus shall constitute an offer to sell
or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such
an offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For
a more complete understanding of the offering of the securities, you should refer to the registration statement, including its
exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should read the entire prospectus and any related issuer
free writing prospectus, as well as the documents incorporated by reference into this prospectus or any related issuer free writing
prospectus, before making an investment decision. Neither the delivery of this prospectus or any issuer free writing prospectus
nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein
or in any issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such issuer free writing
prospectus. You should assume that the information appearing in this prospectus or any document incorporated by reference is accurate
only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities.
Our business, financial condition, results of operations and prospects may have changed since that date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt; text-align: center"><B><A NAME="b_002"></A>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><I>The items in the following summary are described in more
detail later in this prospectus and in the accompanying prospectus. This summary provides an overview of selected information and
does not contain all the information you should consider before investing in our common stock. Therefore, you should read the entire
prospectus and the accompanying prospectus carefully, including the &ldquo;Risk Factors&rdquo; section, and other documents or
information included or incorporated by reference in this prospectus and the accompanying prospectus before making any investment
decision. As used in this prospectus, unless the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo;
or &ldquo;the Company&rdquo; refer to Actinium Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries taken as a whole.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>The Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">Actinium Pharmaceuticals, Inc. is a clinical-stage, biopharmaceutical
company applying its proprietary platform technology and deep understanding of radiobiology to the development of novel targeted
therapies known as ARCs or Antibody Radiation-Conjugates. Radiation is an effective therapeutic modality that is used in the treatment
of over fifty percent of all cancer patients and often combined with chemotherapy and immunotherapy for greater therapeutic effect.
Radiation is typically administered from outside the body, which constrains the amount that can be administered to patients due
to dose-limiting toxicities. In addition, due to the diffuse nature of the external radiation beam, its usage is limited to solid
tumors and cannot be used in blood cancers, which are diffuse. ARCs combine the cell-killing ability of a radioisotope payload
with a targeting agent, such as a monoclonal antibody, or mAb, to deliver radiation inside the body to specific cells, to potentially
generate greater efficacy and less toxicity. ARCs usage is broader than external delivered radiation as they can be used for both
solid tumors and blood cancers. Blood or hematologic cancers are highly sensitive to radiation and our clinical pipeline is focused
on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Our clinical programs
are focused on two primary areas: targeted conditioning prior to a cell or gene therapy procedure and therapeutics, either in combination
with other agents or as a monotherapy. Our product development strategy is actively informed by clinical data with our ARCs in
over 500 patients, including the ongoing SIERRA trial. Our clinical pipeline has emanated from our AWE, or Antibody Warhead Enabling
technology platform, which is protected by over 110 issued and pending patents, trade secrets and know-how and is being utilized
in a collaborative research partnership with Astellas Pharma, Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">We are advancing the only multi-target,
multi-indication clinical-stage pipeline for targeted conditioning and the only ARC-based targeted conditioning regimens in development.
Our ARCs for targeted conditioning are intended to potentially enable improved access to cell-based therapies with curative potential,
including BMT, or bone marrow transplant, ACT, or adoptive cell therapy such as CAR-T, and Gene Therapy, as well as improved outcomes.
Conditioning in the context of BMT, ACT or Gene Therapy is the act of depleting certain blood and immune-forming cells, including
bone marrow stem cells and, in some cases, diseased cells prior to transplanting new cells into a patient. Currently, conditioning
is accomplished using a combination of chemotherapeutic agents and external radiation. These non-targeted conditioning regimens
may prevent a patient from receiving a potentially curative therapy and hinder outcomes due to their toxicities. ARCs have the
potential to increase patient access and outcomes by way of their ability to selectively deplete targeted cells while sparing normal
healthy cells. We use our ARCs at high isotope dose levels to achieve myeloablation, which fully depletes bone marrow stem cells
and at lower isotope dose levels to achieve lymphodepletion, which spares bone marrow stem cells from depletion. In addition, dosing
may be titrated downward from myeloablative doses to achieve partial myeloablation, which may be appropriate for certain gene therapy
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Impact of COVID&ndash;19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">In December 2019, a
novel strain of COVID-19 was reported in China. Since then, COVID-19 has spread globally. The spread of COVID-19 from China to
other countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &ldquo;pandemic,&rdquo;
or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world imposed quarantines and restrictions
on travel and mass gatherings to slow the spread of the virus and closed non-essential businesses, and as of the date of this prospectus,
many local jurisdictions continue to have such restrictions in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">As many local jurisdictions
continue to have such restrictions in place, our ability to continue to operate our business may also be limited. Such events may
result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could
materially affect our business, financial condition and results of operations. In response to COVID-19, we implemented remote working
and thus far have not experienced a significant disruption or delay in our operations as it relates to the clinical development
of our drug candidates. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but
there is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. Therefore, the
COVID-19 pandemic may continue to affect our operation, may further divert the attention and efforts of the medical community to
coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">The spread of COVID-19, which has caused
a broad impact globally, may materially affect us economically. While the ultimate economic impact brought by, and the duration
of, the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted, including new
information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among
others, the pandemic has resulted significant disruptions in the general commercial activity and the global economy and caused
financial market volatility and uncertainty in significant and unforeseen ways in the recent months. A continuation or worsening
of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access
capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from
the spread of COVID-19 could materially affect our business and the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">Currently, the Phase 3 SIERRA trial for
our lead program, Iomab-B, continues to remain active at a majority of our clinical trial sites, with investigators providing feedback
that recruitment and enrollment will remain active because of the acute nature of the disease, the high unmet needs of patients
with relapsed or refractory AML, the potentially curative nature of BMT and the differentiated profile of Iomab-B. Certain sites
that had not been actively enrolling due to COVID-19 have resumed recruitment and enrollment. We also believe our earlier stage
clinical trials for our CD33 program will also continue to recruit and enroll patients given the acute nature of relapsed or refractory
AML. The continuation of the pandemic could adversely affect our planned clinical trial operations, including our ability to conduct
the trials on the expected timelines and recruit and retain patients and principal investigators and site staff who, as healthcare
providers, may have heightened exposure to COVID-19 if their geography is impacted by the pandemic. Further, the continuation and/or
resurgence of the COVID-19 pandemic could result in delays in our clinical trials due to prioritization of hospital resources toward
the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials at this time, or the inability of
patients to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare
services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service
providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the
pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work
for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">Additionally, COVID-19 may result in delays
in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&rsquo;s or Institutional
Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">To date, COVID-19 has not had a financial
impact on our company. However, COVID-19 has caused severe disruptions in transportation and limited access to our facility, resulting
in limited support from our staff and professional advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">The ultimate impact from COVID-19 on our
business operations and financial results during 2020 will depend on, among other things, the ultimate severity and scope of the
pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease,
the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with
which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results
during 2020 and beyond, but developments related to COVID-19 may materially affect us in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt"><B>Corporate and Other Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">We were organized as a corporation in the State of Nevada
in October 1997 and reorganized as a corporation in the State of Delaware in March 2013. Our principal executive offices are located
at 275 Madison Avenue, 7th Floor, New York, New York 10016. Our telephone number is (646) 677-3870. Our website address is www.actiniumpharma.com.
Information accessed through our website is not incorporated into this prospectus and is not a part of this prospectus.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 99%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE OFFERING </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Common stock offered by us </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Shares of our common stock having an aggregate offering price of up to $200,000,000. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Manner of offering </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&ldquo;At the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act, that may be made from time to time on the NYSE American, the existing trading market for our common shares, through JonesTrading, as agent or principal. See section titled &ldquo;Plan of Distribution&rdquo; on page 9 of this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Use of proceeds </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We intend to use the net proceeds from this offering for general corporate purposes, including the advancement of our drug candidates in clinical trials, regulatory submissions, potential commercial activity, preclinical research and development, capital expenditures, and to meet working capital needs. Please see &ldquo;Use of Proceeds&rdquo; on page 7. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Risk factors </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investing in our securities involves a high degree of risk. You should read the &ldquo;Risk
    Factors&rdquo; section beginning on page 4 of this prospectus and in the documents incorporated by reference in this
    prospectus for a discussion of factors to consider before deciding to invest in our common stock. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">NYSE American symbol</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">ATNM.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="b_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>An investment in our common stock involves a high degree
of risk. Before deciding whether to invest in our common stock, you should carefully consider the risks and uncertainties described
below, together with the information under the heading &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form 10-K
for the fiscal year ended December 31, 2019, all of which are incorporated herein by reference, as updated or superseded by the
risks and uncertainties described under similar headings in the other documents that are filed after the date hereof and incorporated
by reference into this prospectus, together with all of the other information contained or incorporated by reference in this prospectus.
The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known
to us or that we currently deem immaterial may also affect our operations. Past financial performance may not be a reliable indicator
of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these
risks actually occurs, our business, business prospects, financial condition or results of operations could be seriously harmed.
This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please
also read carefully the section below entitled &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our management team may invest or spend the proceeds of
this offering in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management will have broad discretion over the use of proceeds
from this offering. We currently intend to use the net proceeds of this offering for general corporate purposes, including the
advancement of our drug candidates in clinical trials, regulatory submissions, potential commercial activity, preclinical research
and development, capital expenditures, and to meet working capital needs. For more information, see &ldquo;Use of Proceeds&rdquo;
on page 7. However, our management will have broad discretion in the application of the net proceeds from this offering and could
spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. You will not
have the opportunity, as part of your investment decision, to assess whether these proceeds are being used appropriately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount and timing of our actual expenditures will depend
upon numerous factors, including the amount of cash generated by our operations, the amount of competition and other operational
factors. The costs and timing of development activities, particularly conducting clinical trials and preclinical studies, are highly
uncertain, subject to substantial risks and can often change. Depending on the outcome of these activities and other unforeseen
events, our plans and priorities may change, and we may apply the net proceeds of this offering in different proportions than we
currently anticipate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our failure to apply these funds effectively could have a material
adverse effect on our business, delay the further development of our product candidates and cause the price of our common shares
to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The failure by management to apply these funds effectively could
result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline
and delay the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Resales of our common stock in the public market during
this offering by our stockholders may cause the market price of our common stock to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue shares of common stock from time to time in connection
with this offering. The issuance from time to time of these new shares of common stock, or our ability to issue new shares of common
stock in this offering, could result in resales of our shares of common stock by our current stockholders concerned about the potential
dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Purchasers in this offering will likely experience immediate
and substantial dilution in the book value of their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares of common stock sold in this offering, if any, will
be sold from time to time at various prices. However, the expected offering price per share of common stock may be substantially
higher than the net tangible book value per share of common stock. Therefore, if you purchase shares of our common stock in this
offering, your interest will be diluted to the extent of the difference between the price per share you pay and the net tangible
book value per share of common stock. Assuming that the sale of an aggregate amount of $200,000,000 of shares of our common stock
in this offering at an assumed offering price of $0.56 per share, which was the last reported sale price of our common stock on
the NYSE American on August 5, 2020, and based on our net tangible book value as of March 31, 2020, if you purchase shares of common
stock in this offering you will suffer substantial and immediate dilution of $0.258 per share in the net tangible book value of
the share common stock. The future exercise of outstanding options, warrants and certain convertible term loans will result in
further dilution of your investment. See the section entitled &ldquo;Dilution&rdquo; below for a more detailed discussion of the
dilution you will incur if you purchase shares of our common stock in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of a substantial number of shares of our common
stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Almost all of our 407,558,060<B>&nbsp;</B>outstanding shares
of common stock as of August 6, 2020, as well as a substantial number of shares of our common stock underlying outstanding options
and warrants, are available for sale in the public market, either pursuant to Rule 144 under the Securities Act, or an effective
registration statement. Pursuant to this shelf registration statement on Form S-3, we may sell up to $500,000,000 of our equity
securities over the next several years. Sales of a substantial number of shares of our common stock in the public markets could
depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.
We cannot predict the effect that future sales of our common stock would have on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The common stock offered hereby will be sold in &quot;at-the-market&quot;
offerings, and investors who buy shares at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;Investors who purchase shares in this offering at different
times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion,
subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price.
Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices
they paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The actual number of shares we will issue under the sales
agreement, at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to certain limitations in the sales agreement and compliance
with applicable law, we have the discretion to deliver placement notices to JonesTrading at any time throughout the term of the
sales agreement. The number of shares that are sold by JonesTrading after delivering a placement notice will fluctuate based on
the market price of the common stock during the sales period and limits we set with JonesTrading. Because the price per share
of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at
this stage to predict the number of shares that will be ultimately issued.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and the information incorporated by reference
in this prospectus contain &ldquo;forward-looking statements,&rdquo; which include information relating to future events, future
financial performance, strategies, expectations, competitive environment and regulation. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo;
and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements
should not be read as a guarantee of future performance or results and will probably not be accurate indications of when such
performance or results will be achieved. Forward-looking statements are based on information we have when those statements are
made or our management&rsquo;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties
that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Important factors that could cause such differences include, but are not limited to:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to complete clinical trials as anticipated and obtain and maintain regulatory approvals for our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to adequately protect our intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">disputes over ownership of intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our products are an attractive alternative to other procedures and products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">entry of new competitors and products and potential technological obsolescence of our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">loss of a key customer or supplier;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">adverse economic conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">adverse federal, state and local government regulation, in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">price increases for supplies and components;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">inability to carry out research, development and commercialization plans; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -6pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">loss or retirement of key executives and research scientists; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">our ability to regain and maintain compliance with the continued listing requirements of the NYSE American and the risk that our common stock will be delisted if we cannot do so;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the geographic, social and economic impact of COVID-19 on the Company&rsquo;s business and liquidity; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">other factors discussed in this prospectus.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should review carefully the section entitled &ldquo;Risk
Factors&rdquo; beginning on page&nbsp;4 of this prospectus for a discussion of these and other risks that relate to our business
and investing in our securities. The forward-looking statements contained or incorporated by reference in this prospectus are
expressly qualified in their entirety by this cautionary statement. Except as required by applicable law, we do not undertake
any obligation to publicly update any forward-looking statement contained in this prospectus, the accompanying prospectus or the
documents incorporated by reference herein to reflect events or circumstances after the date on which any such statement is made
or to reflect the occurrence of unanticipated events. For all forward-looking statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_005"></A>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue and sell shares of common stock having aggregate
sales proceeds of up to $200,000,000 from time to time, before deducting sales agent commissions and expenses. The amount of proceeds
from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold.
There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with JonesTrading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to use the net proceeds from the sale of
securities offered by this prospectus for general corporate purposes, including the advancement of our drug candidates in clinical
trials, regulatory submissions, potential commercial activity, preclinical research and development, capital expenditures, and
to meet working capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors are cautioned, however, that expenditures may vary
substantially from these uses. Investors will be relying on the judgment of our management, who will have broad discretion regarding
the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous factors,
including the amount of cash generated by our operations, the amount of competition and other operational factors. We may find
it necessary or advisable to use portions of the proceeds from this offering for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we evaluate these and other factors and we
anticipate continuing to make such evaluations to determine if the existing allocation of resources, including the proceeds of
this offering, is being optimized. Circumstances that may give rise to a change in the use of proceeds include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">a change in development plan or strategy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the addition of new products or applications;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">technical delays;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">delays or difficulties with our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">negative results from our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">difficulty obtaining U.S. Food and Drug Administration approval; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the availability of other sources of cash including additional offerings, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">Pending other uses, we intend to invest the proceeds to
us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed
obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds invested will yield a favorable, or
any, return.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_006"></A>Dilution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If you invest in our common stock, your
interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net tangible
book value per share of common stock immediately after this offering. The net tangible book value of our common stock as of March
31, 2020, was approximately $2.0 million, or approximately $0.011 per share of common stock based on 174,839,536 shares of common
stock outstanding at that time. &ldquo;Net tangible book value&rdquo; is total assets minus the sum of liabilities and intangible
assets. &ldquo;Net tangible book value per share&rdquo; is net tangible book value divided by the total number of shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our pro forma net tangible book value as of March 31, 2020,
after giving effect to (i) the issuance of 128,333,333 shares of common stock and pre-funded warrants to purchase 82,500,001 shares
of common stock in an underwritten public offering in April 2020 (the &ldquo;April 2020 Offering&rdquo;) and assuming exercise
of all pre-funded warrants sold in the April 2020 Offering at $0.0001 per share, after deducting underwriting discounts and commissions
and estimated offering expenses payable by us in connection with the April 2020 Offering, and (ii) the issuance of 55,653,846 shares
of our common stock and pre-funded warrants to purchase 21,269,231 shares of common stock in a public offering in June 2020 (the
&ldquo;June 2020 Offering&rdquo;) and assuming exercise of all pre-funded warrants sold in the June 2020 Offering at $0.0001 per
share, after deducting placement agent fees and estimated offering expenses payable by us in connection with the June 2020 Offering,
would have been approximately $54.1 million, or approximately $0.117 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">After giving effect to the foregoing pro
forma changes and sale of our common stock in the aggregate amount of $200,000,000 in this offering at an assumed offering price
of $0.56 per share, the last reported sale price of our common stock on the NYSE American on August 5, 2020, and after deducting
the commissions and estimated offering expenses payable by us, our net tangible book value as of March 31, 2020, would have been
approximately $247.9 million, or approximately $0.302 per share of our common stock. This represents an immediate increase in net
tangible book value of $0.291 per share to our existing stockholders and an immediate dilution of approximately $0.258 per share
to new investors participating in this offering, as illustrated by the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Assumed offering price per share of common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.560</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Net tangible book value per share of common stock as of March 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Increase in net tangible book value per share of common stock attributable to the April 2020 Offering and the June 2020 Offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.106</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Pro forma net tangible book value per share as of March 31, 2020, after giving effect to the April 2020 Offering&#9;and the June 2020 Offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Increase in pro forma net tangible book value per share of common stock attributable to the offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.185</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt">Pro forma as adjusted net tangible book value per share of common stock as of March 31, 2020 after giving effect to the April 2020 Offering, the June 2020 Offering and this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.302</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt">Dilution in net tangible book value per share of common stock to new investors in the offering</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.258</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The pro forma and pro forma as adjusted
information is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and
other terms of the offering determined at the time common stock is sold pursuant to this prospectus. The as adjusted and pro forma
as adjusted information assumes that all of our common stock in the aggregate amount of $200,000,000 is sold at the assumed offering
price of $0.56 per share, the last reported sale price of our common stock on the NYSE American on August 5, 2020. The shares sold
in this offering, if any, will be sold from time to time at various prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The discussion and table above are based
on 174,839,536 shares of common stock outstanding as of March 31, 2020, and excludes the following potentially dilutive securities
as of that date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">11,061,071 shares of common stock issuable upon the exercise
of stock options outstanding as of March 31, 2020, under our equity incentive plans, with a weighted average exercise price of
$1.19 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">22,126,299 shares of common stock available for future
grants under our equity incentive plans as of March 31, 2020; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">86,140,575 shares of common stock issuable upon the exercise
of warrants outstanding as of March 31, 2020, with a weighted average exercise price of $0.69 per share.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that any of these options, awards or warrants
are exercised, new options and awards are issued under our equity incentive plans and subsequently exercised or we issue additional
common shares or securities convertible into common shares in the future, there may be further dilution to new investors participating
in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_007"></A>DIVIDENDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 195pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the past, we have not declared or paid cash dividends on
our common stock, and we do not intend to pay any cash dividends on our common stock. Rather, we intend to retain future earnings,
if any, to fund the operation and expansion of our business and for general corporate purposes.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_008"></A>PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 7, 2020, we entered into a Capital on Demand&trade;
Sales Agreement, or the sales agreement, with JonesTrading, pursuant to which we may, from time to time, offer and sell shares
of our common stock having an aggregate offering price of up to $200,000,000. Sales of our common stock, if any, under this prospectus
may be made in sales deemed to be&nbsp;&ldquo;at the market offerings&rdquo;&nbsp;as defined in Rule 415 promulgated under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each time we wish to issue and sell common stock, we will notify
JonesTrading of the number of shares to be issued, the dates on which such sales are anticipated to be made, any minimum price
below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed JonesTrading, unless
JonesTrading declines to accept the terms of the notice, JonesTrading has agreed, subject to the terms and conditions of the sales
agreement, to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares
up to the amount specified on such terms. We may instruct JonesTrading not to sell shares of common stock if the sales cannot be
effected at or above the price designated by us in any such instruction. We or JonesTrading may suspend the offering of shares
of common stock being made through JonesTrading under the sales agreement upon proper notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay JonesTrading commissions for its services in acting
as agent in the sale of our common stock. JonesTrading will be entitled to compensation at a commission rate equal to 3.0% of the
aggregate gross sales price of the shares sold. Because there is no minimum offering amount required as a condition to close this
offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We
have also agreed to reimburse JonesTrading for certain specified expenses, including the fees and disbursements of its legal counsel
in an aggregate amount not to exceed $50,000. We estimate that the total expenses for this offering, excluding compensation and
reimbursements payable to JonesTrading under the terms of the sales agreement, will be approximately $275,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Settlement for sales of common stock will occur on the second
business day following the date on which any sales are made or such earlier day as is industry practice for regular-way trading,
or on some other date that is agreed upon by us and JonesTrading in connection with a particular transaction, in return for payment
of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of the common stock on our behalf,
JonesTrading will be deemed to be an&nbsp;&ldquo;underwriter&rdquo;&nbsp;within the meaning of the Securities Act and the compensation
of JonesTrading will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution
to JonesTrading against certain civil liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering of shares of common stock pursuant to the sales
agreement will terminate upon the earliest of (i) the sale of all shares of common stock subject to the sales agreement and (ii)
the termination of the sales agreement according to its terms by either JonesTrading or us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NYSE American and trades under
the symbol&nbsp;&ldquo;ATNM.&rdquo;&nbsp;The transfer agent of our common stock is Action Stock Transfer Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JonesTrading and/or its affiliates have in the past and may
in the future provide various investment banking and other financial services for us for which services they may in the future
receive customary fees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_009"></A>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the securities offered by this prospectus will
be passed upon by Haynes and Boone, LLP, New York, New York. Duane Morris LLP, New York, New York, is counsel for JonesTrading
in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_010"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P>The financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the fiscal years ended
December 31, 2019 and 2018 have been so incorporated in reliance on the report of Marcum LLP, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_011"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to the informational requirements
of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual, quarterly and current reports, proxy
statements and other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains
a website that contains reports, proxy and information statements and other information regarding registrants that file electronically
with the Securities and Exchange Commission. The address of the Securities and Exchange Commission&rsquo;s website is www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We make available free of charge on or
through our website at www.pulmatrix.com, our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports
on Form&nbsp;8-K and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange
Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish
it to the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have filed with the Securities and Exchange
Commission a registration statement under the Securities Act, relating to the offering of these securities. The registration statement,
including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not
contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement for
free at www.sec.gov. The registration statement and the documents referred to below under &ldquo;Incorporation of Certain Information
By Reference&rdquo; are also available on our website, www.actiniumpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not incorporated by reference into
this prospectus the information on our website, and you should not consider it to be a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_012"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities and Exchange Commission allows us to &ldquo;incorporate
by reference&rdquo; the information we have filed with it, which means that we can disclose important information to you by referring
you to those documents. The information we incorporate by reference is an important part of this prospectus, and later information
that we file with the Securities and Exchange Commission will automatically update and supersede this information. We incorporate
by reference the documents listed below and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01
of Form 8-K) we file with the Securities and Exchange Commission pursuant to Sections l3(a), l3(c), 14 or l5(d) of the Securities
Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior to the termination of the offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011475/f10k2019_actiniumpharma.htm">Form 10-K</A> for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission on May 8, 2020, and as subsequently amended on Form 10-K/A filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015102/f10k2019a1_actiniumpharma.htm">June 16, 2020</A> and on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020017370/f10k2019a2_actiniumpharma.htm">July 13, 2020</A>; </FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020016168/f10q0320_actiniumpharma.htm">Form 10-Q</A> for the quarterly period ended March 31, 2020, filed with the Securities and Exchange Commission on June 29, 2020;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Our Current Reports on
Forms 8-K filed with the Securities and Exchange Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020007702/ea119813-8k_actiniumpharma.htm">March 27, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020010060/ea120946-8k_actiniumpharma.htm">April 24, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011048/ea121215-8k_actiniumpharma.htm">May 5, 2020</A> (<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342-8k_actinium.htm">two reports</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020012670/ea121138-8k_actinium.htm">May 15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121-8k_actiniumpharma.htm">June 16, 2020</A> (<A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015114/ea123040-8k_actiniumpharma.htm">two reports</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189-8k_actiniumpharma.htm">June 18, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015376/ea123229-8k_actinium.htm">June 19, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015376/ea123229-8k_actinium.htm">July 24, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015376/ea123229-8k_actinium.htm">August 5, 2020</A>; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The description of the Company&rsquo;s common stock and warrants contained in the <A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014001685/f8a12b0314_actnium.htm">Form 8-A</A> filed with the Securities and Exchange Commission on March 24, 2014, including any amendments thereto or reports filed for the purposes of updating this description. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All filings filed by us pursuant to the Securities Exchange
Act of 1934, as amended, after the date of the initial filing of this registration statement and prior to the effectiveness of
such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall also be deemed
to be incorporated by reference into the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should rely only on the information incorporated by reference
or provided in this prospectus. We have not authorized anyone else to provide you with different information. Any statement contained
in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for the purposes of this
prospectus to the extent that a later statement contained in this prospectus or in any other document incorporated by reference
into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed,
except as so modified or superseded, to constitute a part of this prospectus. You should not assume that the information in this
prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will provide without charge to each person to whom a copy
of this prospectus is delivered, upon written or oral request, a copy of any or all of the reports or documents that have been
incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings, unless
we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to us at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Steve O&rsquo;Loughlin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">275 Madison Avenue, 7th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(646) 677-3870</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may also access the documents incorporated by reference
in this prospectus through our website at www.actiniumpharma.com. Except for the specific incorporated documents listed above,
no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement
of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$200,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_01.jpg" ALT="img_02" STYLE="height: 149px; width: 624px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_02.jpg" ALT="LOGO" STYLE="height: 41px; width: 138px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58px; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 14.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Other Expenses of Issuance and Distribution.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">The fees and expenses
payable by us in connection with this registration statement are estimated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Securities and Exchange Commission Registration Fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">57,310</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer Agent Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Miscellaneous Fees and Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">242,810</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58px; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 15.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Indemnification of Directors and Officers. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 145 of the
General Corporation Law of the State of Delaware provides, in general, that a corporation incorporated under the laws of the State
of Delaware, as we are, may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending
or completed action, suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the
fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such
action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed
to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe
such person&rsquo;s conduct was unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person
against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by such person in connection with the defense
or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in
or not opposed to the best interests of the corporation, except that no indemnification will be made in respect of any claim, issue
or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the
Court of Chancery of the State of Delaware or any other court in which such action was brought determines such person is fairly
and reasonably entitled to indemnity for such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of
incorporation and bylaws provide that we will indemnify our directors, officers, employees and agents to the extent and in the
manner permitted by the provisions of the General Corporation Law of the State of Delaware, as amended from time to time, subject
to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders&rsquo; or directors&rsquo;
resolution or by contract. Any repeal or modification of these provisions approved by our stockholders will be prospective only
and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such
repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also permitted
to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether
or not the General Corporation Law of the State of Delaware would permit indemnification.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58px; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 16.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Exhibit No.</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 11%; text-align: left">1.1*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 88%; text-align: left">Form of Underwriting Agreement</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">1.2**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="ea125182ex1-2_actinium.htm">Capital on Demand&trade; Sales Agreement, dated August 7, 2020, by and between Actinium Pharmaceuticals, Inc. and JonesTrading Institutional Services LLC</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filed with the SEC on April 17, 2013)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">4.2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm">Certificate of Amendment to Certificate of Incorporation filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm">Certificate of Amendment to Certificate of Incorporation filed February 3, 2014 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">4.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm">Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm">Certificate of Amendment to Actinium&rsquo;s Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">4.6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm">Certificate of Amendment to Actinium&rsquo;s Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">4.8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm">Amendment to the Amended and Restated Bylaws, dated May 5, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">4.10*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Certificate of Designation of Preferred Stock</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.11*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Warrant Agreement (including form of Warrant)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">4.12*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Unit Agreement (including form of Unit)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">4.13*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Subscription Rights Agreement (including form of Subscription Rights Certificate)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">5.1**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="ea125182ex5-1_actinium.htm">Opinion of Haynes and Boone LLP</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">23.1**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="ea125182ex23-1_actinium.htm">Consent of Marcum LLP, Independent Registered Public Accounting Firm</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">23.2**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="ea125182ex5-1_actinium.htm">Consent of Haynes and Boone LLP (included in Exhibit 5.1)</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">24.1**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="#poa">Power of Attorney (incorporated by reference to the signature page of this Registration Statement)</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">To be filed, if necessary, by an amendment to the registration
statement or incorporated by reference to a Current Report on Form 8-K filed in connection with an underwritten offering of the
shares offered hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: left">Filed herewith.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 58px; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 17.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Undertakings.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned registrant
hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(a) (1)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 77px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 77px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="padding-bottom: 0.75pt; text-align: left"><FONT STYLE="font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 77px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"><I>provided, however, </I>that
the undertakings set forth in paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required to
be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission
by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference
in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">If the registrant is relying on Rule 430B (&sect;230.430B of this chapter):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 120px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 120px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">(b) The undersigned
registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the
registrant&rsquo;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to section 15(d) of the Securities Exchange
Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">(c) Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">(d) The undersigned
registrant hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of New York, State of New York, on August 7, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">ACTINIUM PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 35%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding-bottom: 0; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Sandesh Seth</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 60%; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 35%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding-bottom: 0; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Steve O&rsquo;Loughlin</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="poa"></A>Power of Attorney</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below hereby constitutes and appoints each of Sandesh Seth and Steve O&rsquo;Loughlin, severally,
acting alone and without the other, his or her true and lawful attorney-in-fact and agent, each with full power of substitution,
for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective
amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority
to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents
and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents,
or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 18%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Sandesh Seth</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Chairman and Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">August 7, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Sandesh Seth</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(principal executive officer)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Steve O&rsquo;Loughlin</I></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">August 7, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(principal financial and accounting officer)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Jeffrey Chell</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">August 7, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Jeffrey Chell</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ David Nicholson</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">August 7, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">David Nicholson</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Richard I. Steinhart</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">August 7, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Richard I. Steinhart</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><I>/s/ Ajit J. Shetty</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">August 7, 2020</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Ajit J. Shetty</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>2
<FILENAME>ea125182ex1-2_actinium.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
1.2</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
PHARMACEUTICALS, INC. </B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($0.001
par value per share)</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;Capital
on Demand<FONT STYLE="font-weight: normal">&trade;</FONT> Sales Agreement</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
7, 2020</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JonesTrading
Institutional Services LLC</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">757
Third Avenue, 23rd Floor</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 4.5in 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10017</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 4.5in 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;)
with JonesTrading Institutional Services LLC (the &ldquo;<U>Agent</U>&rdquo;), as follows:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Issuance and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms
and subject to the conditions set forth herein, it may issue and sell through or to the Agent, as agent or principal, shares (the
&ldquo;<U>Placement Shares</U>&rdquo;) of common stock of the Company, $0.001 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;),
<I>provided, however</I>, that in no event shall the Company issue or sell, through or to Agent, Placement Shares for an aggregate
gross sales proceeds that would exceed (a) the dollar amount of shares of Common Stock registered on the Registration Statement
(as defined below), (b) the number of authorized but unissued shares of Common Stock, or (c) the dollar amount of shares of Common
Stock permitted to be sold under Form S-3, or (d) the dollar amount of shares of Common Stock for which the Company has filed
a Prospectus (as defined below) (the least of (a), (b), (c) and (d), the &ldquo;<U>Maximum Amount</U>&rdquo;). Notwithstanding
anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section
1 on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that
Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares hereunder will be
effected pursuant to the Registration Statement and at no earlier time than such time as the Registration Statement shall have
been declared effective by the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;), although nothing in this
Agreement shall be construed as requiring the Company to issue any Placement Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date hereof, the Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the
rules and regulations thereunder (the &ldquo;<U>Securities Act</U>&rdquo;), with the Commission a registration statement on Form
S-3, including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time
by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions
of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &ldquo;<U>Exchange Act</U>&rdquo;).
The prospectus included as part of the registration statement relates solely to the Placement Shares (the &ldquo;Placement <U>Prospectus</U>&rdquo;).
The Company will furnish to the Agent, for use by the Agent, copies of the Placement Prospectus. Except where the context otherwise
requires, such registration statement, and any post-effective amendment thereto, including all documents filed as part thereof
or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently
filed with the Commission pursuant to Rule&nbsp;424(b) under the Securities Act or deemed to be a part of such registration statement
pursuant to Rule&nbsp;430B or 462(b) under the Securities Act or any subsequent registration statement on Form S-3 filed pursuant
to Rule 415(a)(6) under the Securities Act by the Company to cover any Placement Shares, as a result of the end of the three-year
period described in Rule 415(a)(5) of the Securities Act, is herein called the &ldquo;<U>Registration Statement</U>.&rdquo; The
Placement Prospectus, including all documents incorporated therein by reference, to the extent such information has not been superseded
or modified in accordance with Rule 412 under the Securities Act (as qualified by Rule 430B(g) of the Securities Act), included
in the Registration Statement, as it may be supplemented by one or more prospectus supplements together with any then issued Issuer
Free Writing Prospectus (defined below), is herein called the &ldquo;<U>Prospectus</U>.&rdquo; Any reference herein to the Registration
Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated
by reference therein, and any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo;
with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution
hereof of any document with the Commission deemed to be incorporated by reference therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference herein to the Registration Statement, the Placement Prospectus, the Prospectus or any Issuer Free Writing Prospectus
shall be deemed to refer to and include the documents, if any, incorporated by reference therein (the &ldquo;<U>Incorporated Documents</U>&rdquo;),
including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any
reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration
Statement, the Placement Prospectus, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include
the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or
the date of the Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference.
For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement
thereto shall be deemed to include any copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval
system, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &ldquo;<U>EDGAR</U>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Placements</U>. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &ldquo;<U>Placement</U>&rdquo;),
it will notify the Agent by email notice (or other method mutually agreed to in writing by the Parties) of the number or dollar
value of Placement Shares to be sold, the time period during which sales are requested to be made, any limitation on the number
of Placement Shares that may be sold in any one Trading Day and any minimum price below which sales may not be made (a &ldquo;<U>Placement
Notice</U>&rdquo;), the form of which is attached hereto as Schedule 1. The Placement Notice shall originate from any of the individuals
from the Company set forth on Schedule 3 (with a copy to each of the other individuals from the Company listed on such schedule),
and shall be addressed to each of the individuals from the Agent set forth on Schedule 3, as such Schedule 3 may be amended from
time to time. The Placement Notice shall be effective unless and until (i)&nbsp;the Agent declines to accept the terms contained
therein for any reason, in its sole discretion, (ii)&nbsp;the entire amount of the Placement Shares to be sold thereunder have
been sold, (iii)&nbsp;the Company suspends or terminates the Placement Notice for any reason, in its sole discretion, (iv) the
Company issues a subsequent Placement Notice with parameters superseding those of the earlier dated Placement Notice, or (v)&nbsp;this
Agreement has been terminated under the provisions of Section 12. The amount of any discount, commission or other compensation
to be paid by the Company to the Agent in connection with the sale of the Placement Shares shall be calculated in accordance with
the terms set forth in Schedule 2. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any
obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice
to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the
terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement
Notice, the terms of the Placement Notice will control.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sale of Placement Shares by the Agent</U>. Subject to the provisions of <U>Section 5(a)</U>, the Agent, for the period specified
in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and
applicable state and federal laws, rules and regulations and the rules of the NYSE American (the &ldquo;<U>Exchange</U>&rdquo;),
to sell the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of such Placement Notice.
The Agent will provide written confirmation to the Company no later than the opening of the Trading Day immediately following
the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on
such day, the compensation payable by the Company to the Agent pursuant to <U>Section 2</U> with respect to such sales, and the
Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Agent (as set forth
in <U>Section 5(b)</U>) from the gross proceeds that it receives from such sales. Subject to the terms of the Placement Notice,
the Agent may sell Placement Shares by any method permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined
in Rule&nbsp;415(a)(4) under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Suspension of Sales</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals
of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged by any of the individuals
to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission
or email correspondence to each of the individuals of the other party set forth on Schedule 3), suspend any sale of Placement
Shares; <I>provided, however</I>, that such suspension shall not affect or impair any party&rsquo;s obligations with respect to
any Placement Shares sold hereunder prior to the receipt of such notice. Each party agrees that no such notice under this Section
4 shall be effective against any other party unless it is made to one of the individuals named on Schedule 3 hereto as associated
with such other party, as such Schedule may be amended in writing from time to time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sale and Delivery to the Agent; Settlement</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sale of Placement Shares</U><I>. </I> On the basis of the representations and warranties herein contained and subject to the
terms and conditions herein set forth, upon the Agent&rsquo;s acceptance of the terms of a Placement Notice, and unless the sale
of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of
this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent
with its normal trading and sales practices to sell such Placement Shares up to the amount specified in such Placement Notice,
and otherwise in accordance with the terms of such Placement Notice. The Company acknowledges and agrees that (i) there can be
no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent will incur no liability or obligation
to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent
to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations
to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement
Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by the Agent and the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Settlement of Placement Shares</U><I>. </I> Unless otherwise specified in the applicable Placement Notice, settlement for sales
of Placement Shares will occur on the second (2<SUP>nd</SUP>) Trading Day (or such earlier day as is industry practice for regular-way
trading) following the date on which such sales are made (each, a &ldquo;<U>Settlement Date</U>&rdquo;). The amount of proceeds
to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &ldquo;<U>Net Proceeds</U>&rdquo;)
will be equal to the aggregate sales price received by the Agent, after deduction for (i) the Agent&rsquo;s commission, discount
or other compensation for such sales payable by the Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed
by any governmental or self-regulatory organization in respect of such sales.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 <U>Delivery of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to,
electronically transfer the Placement Shares being sold by crediting the Agent&rsquo;s or its designee&rsquo;s account (provided
the Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date)
at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may
be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in
good deliverable form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an account
designated by the Company on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent
(if applicable), defaults in its obligation to deliver Placement Shares on a Settlement Date through no fault of the Agent, the
Company agrees that in addition to and in no way limiting the rights and obligations set forth in Section 10(a) hereto, it will
(i) hold the Agent harmless against any loss, claim, damage, or reasonable and documented expense (including reasonable and documented
legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent
(if applicable) and (ii) pay to the Agent (without duplication) any commission, discount, or other compensation to which it would
otherwise have been entitled absent such default.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Limitations on Offering Size</U><I>. </I>Under no circumstances shall the Company cause or request the offer or sale of any
Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement
Shares sold pursuant to this Agreement would exceed the lesser of (A)&nbsp;together with all sales of Placement Shares under this
Agreement, the Maximum Amount and (B)&nbsp;the amount authorized from time to time to be issued and sold under this Agreement
by the Company&rsquo;s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified
to the Agent in writing. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant
to this Agreement at a price lower than the minimum price authorized from time to time by the Company&rsquo;s board of directors,
duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Further, under
no circumstances shall the Company cause or permit the aggregate gross sales proceeds of Placement Shares sold pursuant to this
Agreement to exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Warranties of the Company</U>. Except as disclosed in the Registration Statement or Prospectus (including
the Incorporated Documents), the Company represents and warrants to, and agrees with the Agent that as of the date of this Agreement
and as of each Applicable Time (as defined below), unless such representation, warranty or agreement specifies otherwise:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Registration Statement and Prospectus</U>. As of the date of this Agreement, the Company and the transactions contemplated
by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3 under the Securities Act. The
Registration Statement has been or will be filed with the Commission and has been or will be declared effective by the Commission
under the Securities Act prior to the issuance of any Placement Notice by the Company. The Placement Prospectus will name Agent
as agent, in the section entitled &ldquo;Plan of Distribution.&rdquo; The Company has not received, and has no notice of, any
order of the Commission preventing or suspending the use of the Registration Statement, or threatening or instituting proceedings
for that purpose. The Registration Statement and the offer and sale of Placement Shares as contemplated hereby meet the requirements
of Rule&nbsp;415 under the Securities Act and comply in all material respects with said Rule. Any statutes, regulations, contracts
or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits
to the Registration Statement have been or will be so described or filed. Copies of the Registration Statement, the Prospectus,
and any such amendments or supplements and all documents incorporated by reference therein that were filed with the Commission
on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to the Agent and its counsel. The
Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the
Placement Shares, will not distribute any offering material in connection with the offering or sale of the Placement Shares other
than the Registration Statement and the Prospectus and any Issuer Free Writing Prospectus to which the Agent has consented. The
Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act, delisting the Common Stock from the Exchange, nor has the Company received any notification that the Commission
or the Exchange is contemplating terminating such registration or listing. To the Company's knowledge, it is in compliance with
all applicable listing requirements of the Exchange. The Company has no reason to believe that it will not in the foreseeable
future continue to be in compliance with all such listing and maintenance requirements.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Misstatement or Omission</U>. The Registration Statement, when it became or becomes effective, and the Prospectus, and any
amendment or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all
material respects with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus,
as of such date, will conform in all material respects with the requirements of the Securities Act. The Registration Statement,
when it became or becomes effective, did not, and will not, contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus and any
amendment or supplement thereto, on the date thereof and at each Applicable Time (defined below), did not and will not include
an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. The documents incorporated by reference in the Prospectus did not,
and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue
statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the
statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall not
apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished
to the Company by Agent specifically for use in the preparation thereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Conformity with Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus
or any amendment or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission
under the Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed
and will conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Financial Information</U>. The financial statements of the Company included or incorporated by reference in the Registration
Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, present
fairly, in all material respects, the financial position of the Company and the Subsidiaries (as defined below) as of the dates
indicated and the results of operations, cash flows and changes in stockholders&rsquo; equity of the Company and the Subsidiaries
for the periods specified (subject, in the case of unaudited interim financial statements, to normal year-end audit adjustments)
and have been prepared in compliance with the requirements of the Securities Act and Exchange Act and in conformity with GAAP
(as defined below) applied on a consistent basis (except for (i) such adjustments to accounting standards and practices as are
noted therein, (ii) in the case of unaudited interim financial statements, to the extent such financial statements may not include
footnotes required by GAAP or may be condensed or summary statements and (iii) such adjustments which will not be material, either
individually or in the aggregate) during the periods involved. The summary and selected financial data with respect to the Company
and the Subsidiaries contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free
Writing Prospectuses, if any, fairly present in all material respects the information shown therein as of the respective dates
and for the respective periods specified and are derived from the financial statements set forth in the Registration Statement
and the Prospectus and the other books and records of the Company. There are no financial statements that are required to be included
or incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated by reference
as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), and the Prospectus.
All disclosures contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing
Prospectuses, if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations
of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the
Securities Act, to the extent applicable.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Conformity with EDGAR Filing</U>. The Prospectus delivered to the Agent for use in connection with the sale of the Placement
Shares pursuant to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission
for filing via EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Organization</U>. The Company and its Subsidiaries, if any, are, and will be, duly organized, validly existing as a corporation
and in good standing under the laws of their respective jurisdictions of organization. Each of the Company and the Subsidiaries
is duly licensed or qualified as a foreign corporation for transaction of business and in good standing under the laws of each
other jurisdiction in which its ownership or lease of property or the conduct of its business requires such license or qualification,
and has all corporate power and authority necessary to own or hold its properties and to conduct its business as described in
the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power
or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have
a material adverse effect on or affecting the assets, business, operations, earnings, properties, financial condition, prospects,
stockholders&rsquo; equity or results of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially
interfere with consummation of the transactions contemplated hereby (a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Subsidiaries</U>. The Company&rsquo;s only Subsidiaries, if any, are set forth on Exhibit 21.1 to the Company&rsquo;s Annual
Report on Form 10-K for the most recently ended fiscal year. The Company owns directly or indirectly, all of the equity interests
of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction,
and all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and
similar rights.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Violation or Default</U>. Neither the Company nor any Subsidiary is (i)&nbsp;in violation of its charter or by-laws or similar
organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute
such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement or other agreement or instrument to which the Company or any Subsidiary is a party or by which the
Company or any Subsidiary is bound or to which any of the property or assets of the Company or any Subsidiary is subject; or (iii)&nbsp;in
violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory
authority, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default that would not, individually
or in the aggregate, have a Material Adverse Effect. To the Company&rsquo;s knowledge, no other party under any material contract
or other agreement to which it or any Subsidiary is a party is in default in any respect thereunder where such default would have
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Material Adverse Effect</U>. Subsequent to the latest date of which information is given in the Registration Statement,
the Prospectus and the Issuer Free Writing Prospectuses, if any, (including any document deemed incorporated by reference therein),
there has not been (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably expects will
result in a Material Adverse Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole,
(iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company
or the Subsidiaries which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital
stock or outstanding long-term indebtedness of the Company or the Subsidiaries (other than (A) the grant of awards under equity
incentive plans, (B) changes in the number of shares of outstanding Common Stock due to exercise or conversion of securities exercisable
for or convertible into Common Stock outstanding as of the date of this Agreement, (C) any repurchase of capital stock of the
Company, (D) as a result of the sale of Placement Shares or (E) other than as publicly reported or announced) or (v) any dividend
or distribution of any kind declared, paid or made on the capital stock of the Company or any Subsidiary, other than in each case
above in the ordinary course of business or as otherwise disclosed in the Registration Statement or Prospectus (including any
document deemed incorporated by reference therein).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Capitalization</U>. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid
and non-assessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive
rights, rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set
forth in the Registration Statement and the Prospectus as of the dates referred to therein (other than the grant of options and
restricted stock units under the Company&rsquo;s existing stock option plans, or changes in the number of outstanding shares of
Common Stock of the Company due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible
into, Common Stock outstanding on the date hereof) and such authorized capital stock conforms in all material respects to the
description thereof set forth in the Registration Statement and the Prospectus. The description of the securities of the Company
in the Registration Statement and the Prospectus is complete and accurate in all material respects. Except as disclosed in the
Registration Statement or the Prospectus, as of the date referred to therein, the Company does not have outstanding any options
to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for,
or any contracts or commitments to issue or sell, any shares of capital stock or other securities.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Authorization; Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform
the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a
legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally
and by general equitable principles.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Authorization of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to the terms approved by the
board of directors of the Company or a duly authorized committee thereof, against payment therefor as provided herein, will be
duly authorized, validly issued and fully paid and non-assessable, free and clear of any pledge, lien, encumbrance, security interest
or other claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar
rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when issued, will conform in
all material respects to the description thereof set forth in or incorporated into the Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any court or
arbitrator or governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery
and performance by the Company this Agreement, the issuance and sale by the Company of the Placement Shares, except for such consents,
approvals, authorizations, orders and registrations or qualifications as may been obtained or be required under applicable state
securities laws or by the by-laws and rules of the Financial Industry Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;) or the
Exchange in connection with the sale of the Placement Shares by the Agent.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Preferential Rights</U>. (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities
Act (each, a &ldquo;<U>Person</U>&rdquo;), has the right, contractual or otherwise, to cause the Company to issue or sell to such
Person any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise
or conversion of options or warrants to purchase Common Stock or other securities convertible into or exercisable or exchangeable
for Common Stock), (ii)&nbsp;no Person has any preemptive rights, rights of first refusal, or any other similar rights (whether
pursuant to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common Stock or shares of any other capital stock
or other securities of the Company, (iii) no Person has the right to act as an underwriter or as a financial advisor to the Company
in connection with the offer and sale of the Placement Shares, and (iv)&nbsp;no Person has the right, contractual or otherwise,
to require the Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities
of the Company, or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby,
whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated
thereby or otherwise, except for such rights as have been or will be duly waived on or prior to the date hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Independent Public Accountant</U>. Marcum LLP (the &ldquo;Accountant&rdquo;), whose report on the financial statements of the
Company is filed with the Commission as part of the Company&rsquo;s most recent Annual Report on Form 10-K filed with the Commission
and incorporated by reference into the Registration Statement and the Prospectus, are and, during the periods covered by their
report, were an independent registered public accounting firm with respect to the Company within the meaning of the Securities
Act and the Public Company Accounting Oversight Board (United States). To the Company&rsquo;s knowledge, the Accountant is not
in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;)
with respect to the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Enforceability of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus,
other than such agreements that have expired by their terms or the termination of which is disclosed in documents filed by the
Company on EDGAR, are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms,
except to the extent that (i)&nbsp;enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors&rsquo; rights generally and by general equitable principles and (ii)&nbsp;the indemnification provisions
of certain agreements may be limited by federal or state securities laws or public policy considerations in respect thereof; except
for any unenforceability that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Litigation</U>. There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company&rsquo;s
knowledge, any legal, governmental or regulatory investigations, to which the Company or any Subsidiary is a party or to which
any property of the Company or any Subsidiary is the subject that, individually or in the aggregate, if determined adversely to
the Company or any Subsidiary, would have a Material Adverse Effect or materially and adversely affect the ability of the Company
to perform its obligations under this Agreement; to the Company&rsquo;s knowledge, no such actions, suits or proceedings are threatened
or contemplated by any governmental or regulatory authority or threatened by others that, individually or in the aggregate, if
determined adversely to the Company or any Subsidiary, would reasonably be expected to have a Material Adverse Effect; and (i)&nbsp;there
are no current or pending legal, governmental or regulatory audits or investigations, actions, suits or proceedings that are required
under the Securities Act to be described in the Prospectus that are not so described; and (ii)&nbsp;there are no contracts or
other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement that are not
so filed.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Licenses and Permits</U>. The Company and the Subsidiaries have made all filings, applications and submissions required by,
possesses and is operating in compliance with, all approvals, licenses, certificates, consents, orders, permits and other authorizations
issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement and the Prospectus (the &ldquo;<U>Permits</U>&rdquo;), except where the failure to
possess, obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company
nor any Subsidiary has received written notice of any proceeding relating to revocation or modification of any such Permit or
has any reason to believe that such Permit will not be renewed in the ordinary course, except where the failure to obtain any
such renewal would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Regulatory Filings</U>. The Company has not failed to file with the applicable regulatory authorities any required filing,
declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect; all such filings, declarations, listings, registrations, reports
or submissions were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory
authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies
that, individually or in the aggregate, would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Market Capitalization</U>. (i) At the time of filing the Registration Statement and (ii)&nbsp;at the time of the most recent
amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment was by post-effective
amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus), the Company met
the then applicable requirements for use of Form S-3 under the Securities Act, including compliance with General Instruction I.B.1
of Form S-3, as applicable. The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been
a shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed
current Form 10 information (as defined in Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months previously
reflecting its status as an entity that is not a shell company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Material Defaults</U>. Neither the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed
money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange
Act since the filing of its last Annual Report on Form 10-K, indicating that it (i)&nbsp;has failed to pay any dividend or sinking
fund installment on preferred stock or (ii)&nbsp;has defaulted on any installment on indebtedness for borrowed money or on any
rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Certain Market Activities</U>. Neither the Company, any Subsidiary nor any of its directors, officers or controlling persons
has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be expected to cause or result
in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Placement Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Broker/Dealer Relationships</U>. Neither the Company, any of its Subsidiaries, nor any of the Company&rsquo;s affiliates (i)&nbsp;is
required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo; in accordance with the provisions of the Exchange Act or
(ii)&nbsp;directly or indirectly through one or more intermediaries, controls or is a &ldquo;person associated with a member&rdquo;
or &ldquo;associated person of a member&rdquo; (within the meaning set forth in the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Reliance</U>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting
advice in connection with the offering and sale of the Placement Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Taxes</U>. The Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not
being contested in good faith, except where the failure to file or pay would not have a Material Adverse Effect. Except as otherwise
disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined adversely
to the Company or any Subsidiary which has had, individually or in the aggregate, a Material Adverse Effect. The Company has no
knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been asserted or threatened
against it which would reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Title to Real and Personal Property</U>. The Company and the Subsidiaries have good and marketable title to all items of real
property owned by them and good and valid title to all personal property described in the Registration Statement or Prospectus
as being owned by them that are material to the businesses of the Company or such Subsidiary, in each case free and clear of all
liens, encumbrances and claims, except those that (i) do not materially interfere with the use made and proposed to be made of
such property by the Company and the Subsidiaries or (ii) would not, individually or in the aggregate, have a Material Adverse
Effect. Any real property described in the Registration Statement or Prospectus as being leased by the Company and the Subsidiaries
is held by them under valid, existing and enforceable leases, except those that (A)&nbsp;do not materially interfere with the
use made or proposed to be made of such property by the Company or the Subsidiaries or (B) would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Intellectual Property</U>. The Company and the Subsidiaries own or possess enforceable rights to use all patents, patent applications,
trademarks (both registered and unregistered), service marks, trade names, trademark registrations, service mark registrations,
copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) (collectively, the &ldquo;<U>Intellectual Property</U>&rdquo;), necessary for the conduct
of their respective businesses as conducted as of the date hereof, except to the extent that the failure to own or possess adequate
rights to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; neither the Company nor any Subsidiary has received any written notice of any claim of infringement or conflict
which asserted Intellectual Property rights of others, which infringement or conflict, if the subject of an unfavorable decision,
would result in a Material Adverse Effect; there are no pending, or to the Company&rsquo;s knowledge, threatened judicial proceedings
or interference proceedings challenging the Company&rsquo;s or any Subsidiary&rsquo;s rights in or to or the validity of the scope
of any of the Company&rsquo;s or any Subsidiary&rsquo;s patents, patent applications or proprietary information, except if such
proceedings would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Environmental Laws</U>. Except as set forth in the Registration Statement or the Prospectus, the Company and the Subsidiaries
(i) are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders
relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received and are in compliance with all permits,
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses as described
in the Registration Statement and the Prospectus; and (iii) have not received notice of any actual or potential liability for
the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,
except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required
permits, licenses, other approvals or liability as would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Disclosure Controls</U>. The Company maintains systems of internal controls designed to provide reasonable assurance that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions are recorded as
necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain
asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. The Company is not aware of any material weaknesses in its internal
control over financial reporting (other than as set forth in the Prospectus or the Incorporated Documents). Since the date of
the latest audited financial statements of the Company included in the Prospectus, there has been no change in the Company&rsquo;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting (other than as set forth in the Prospectus). The Company has established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls
and procedures to ensure that material information relating to the Company is made known to the certifying officers by others
within those entities, particularly during the period in which the Company&rsquo;s Annual Report on Form 10-K or Quarterly Report
on Form 10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the Company&rsquo;s disclosure controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K
for the fiscal year most recently ended (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its Form
10-K for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant
changes in the Company&rsquo;s internal controls or, to the Company&rsquo;s knowledge, in other factors that would be reasonably
expected to significantly affect the Company&rsquo;s internal controls. To the knowledge of the Company, the Company&rsquo;s &ldquo;internal
controls over financial reporting&rdquo; and &ldquo;disclosure controls and procedures&rdquo; are effective.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sarbanes-Oxley</U>. There has been no failure on the part of the Company or, any of the Company&rsquo;s directors or officers,
in their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act and the applicable rules and regulations
promulgated thereunder in all material respects. Each of the principal executive officer and the principal financial officer of
the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company
as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports,
schedules, forms, statements and other documents required to be filed by it or furnished by it to the Commission during the 12
months prior to the date of this Agreement. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo;
and &ldquo;principal financial officer&rdquo; shall have the meanings given to such terms in the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Finder&rsquo;s Fees</U>. Neither the Company nor any Subsidiary has incurred any liability for any finder&rsquo;s fees, brokerage
commissions or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect
to Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Labor Disputes</U>. No labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the knowledge
of the Company, is threatened which would have a Material Adverse Effect</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Investment Company Act</U>. Neither the Company or any Subsidiary is or, after giving effect to the offering and sale of the
Placement Shares, will it be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment
company,&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<U>Investment Company
Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Operations</U>. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with
applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions to which the Company or the Subsidiaries are subject, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), except as would not have a Material Adverse
Effect; and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Off-Balance Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the
Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited
to, any structured finance, special purpose or limited purpose entity (each, an &ldquo;<U>Off Balance Sheet Transaction</U>&rdquo;)
that would reasonably be expected to affect materially the Company&rsquo;s liquidity or the availability of or requirements for
its capital resources required to be described in the Prospectus which have not been described as required.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Other Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &ldquo;at the
market&rdquo; or continuous equity transaction other than this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>ERISA</U>. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;), that is maintained, administered or
contributed to by the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has
been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,
including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;); no prohibited
transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material
liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative
exemption; and for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no
&ldquo;accumulated funding deficiency&rdquo; as defined in Section 412 of the Code has been incurred, whether or not waived, and
the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds
the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Forward Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) (a &ldquo;<U>Forward Looking Statement</U>&rdquo;) contained in the Registration Statement and the Prospectus
(i) has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith, and (iii) been prepared
in accordance with Item 10 of Regulation S-K under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Agent Purchases</U>. The Company acknowledges and agrees that Agent has informed the Company that the Agent may, to the extent
permitted under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while this Agreement
is in effect, provided, that (i)&nbsp;no such purchase or sales shall take place while a Placement Notice is in effect (except
to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &ldquo;riskless
principal&rdquo; or in a similar capacity) <FONT STYLE="background-color: white">and (ii)</FONT>&nbsp;the Company shall not be
deemed to have authorized or consented to any such purchases or sales by the Agent.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Margin Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof
by the Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of
Governors of the Federal Reserve System or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Insurance</U>. The Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks
as the Company and the Subsidiaries reasonably believe is adequate for the conduct of their business and as is customary for companies
of similar size engaged in similar businesses in similar industries.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Improper Practices</U>. (i) Neither the Company nor, to the Company&rsquo;s knowledge, the Subsidiaries nor any of their
respective executive officers has, in the past five years, made any unlawful contributions to any candidate for any political
office (or failed fully to disclose any contribution in violation of law) or made any contribution or other payment to any official
of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public
duty in violation of any law or of the character required to be disclosed in the Prospectus; (ii) no relationship, direct or indirect,
exists between or among the Company or, to the Company&rsquo;s knowledge, the Subsidiaries or any affiliate of any of them, on
the one hand, and the directors, officers and stockholders of the Company or, to the Company&rsquo;s knowledge, the Subsidiaries,
on the other hand, that is required by the Securities Act to be described in the Registration Statement and the Prospectus that
is not so described; (iii) no relationship, direct or indirect, exists between or among the Company or the Subsidiaries or, to
the Company&rsquo;s knowledge, any affiliate of them, on the one hand, and the directors, officers or stockholders of the Company
or, to the Company&rsquo;s knowledge, the Subsidiaries, on the other hand, that is required by the rules of FINRA to be described
in the Registration Statement and the Prospectus that is not so described; (iv) there are no material outstanding loans or advances
or material guarantees of indebtedness by the Company or, to the Company&rsquo;s knowledge, the Subsidiaries to or for the benefit
of any of their respective officers or directors or any of the members of the families of any of them; (v) the Company has not
offered, or caused any placement agent to offer, Common Stock to any person with the intent to influence unlawfully (A) a customer
or supplier of the Company or the Subsidiaries to alter the customer&rsquo;s or supplier&rsquo;s level or type of business with
the Company or the Subsidiaries or (B) a trade journalist or publication to write or publish favorable information about the Company
or the Subsidiaries or any of their respective products or services, and, (vi) neither the Company nor the Subsidiaries nor, to
the Company&rsquo;s knowledge, any employee or agent of the Company or the Subsidiaries has made any payment of funds of the Company
or the Subsidiaries or received or retained any funds in violation of any law, rule or regulation (including, without limitation,
the Foreign Corrupt Practices Act of 1977), which payment, receipt or retention of funds is of a character required to be disclosed
in the Registration Statement or the Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Status Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities
Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue
date and as of each Applicable Time (as defined below), did not, does not and will not, through the completion of the Placement
for which such Issuer Free Writing Prospectus is used or deemed used, include any information that conflicted, conflicts or will
conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated document deemed
to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions
from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by the
Agent specifically for use therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Conflicts</U>. Neither the execution of this Agreement by the Company, nor the issuance, offering or sale of the Placement
Shares, nor the consummation of any of the transactions contemplated herein, nor the compliance by the Company with the terms
and provisions hereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted
or will constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be
bound or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as
may have been waived and (ii) such conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such
action result (x) in any violation of the provisions of the organizational or governing documents of the Company, or (y) in any
violation of the provisions of any statute or any order, rule or regulation applicable to the Company or of any court or of any
federal, state or other regulatory authority or other government body having jurisdiction over the Company, other than in each
case any such conflict, breach or violation that, individually or in the aggregate, which would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compliance with Applicable Laws</U>. The Company and the Subsidiaries: (A) are and at all times have been in compliance with
all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use,
distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development,
manufactured or distributed by the Company or the Subsidiaries (&ldquo;<U>Applicable Laws</U>&rdquo;) except where the failure
to be so in compliance would not reasonably be expected to result in a Material Adverse Effect, (b) have not received any Form
483 from the FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European
Medicines Agency (the &ldquo;<U>EMA</U>&rdquo;), or any other federal, state, local or foreign governmental or regulatory authority
alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;), which
would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; (C) possess all material
Authorizations for the Company&rsquo;s current state of product development as disclosed in the Registration Statement, and such
Authorizations are valid and in full force and effect and neither the Company nor the Subsidiaries is in material violation of
any term of any such Authorizations; (D) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from the FDA, the EMA, or any other federal, state, local or foreign governmental or
regulatory authority or third party alleging that any Company product, operation or activity is in material violation of any Applicable
Laws or Authorizations and has no knowledge that the FDA, the EMA, or any other federal, state, local or foreign governmental
or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or
proceeding against the Company; (E) have not received notice that the FDA, EMA, or any other federal, state, local or foreign
governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material
Authorizations and has no knowledge that the FDA, EMA, or any other federal, state, local or foreign governmental or regulatory
authority is considering such action; and (F) have filed, obtained, maintained or submitted all reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
for the Company&rsquo;s current state of product development as disclosed in the registration Statement, except where the failure
to file such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would
not result in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented
by a subsequent submission).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Clinical Studies</U>. All animal and other preclinical studies and clinical trials conducted by the Company or to the Company&rsquo;s
knowledge on behalf of the Company were, and, if still pending are, to the Company&rsquo;s knowledge, being conducted in all material
respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally
used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products
to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained
in the Registration Statement and the Prospectus are accurate in all material respects, and, except as set forth in the Registration
Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of
which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration
Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received
any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the
termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described
in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the
Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compliance Program.</U> The Company has taken such steps as the Company, believes are reasonable and appropriate to comply
in all material respects with applicable regulatory guidelines (including, without limitation, those administered by the FDA,
the EMA, and any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those
performed by the FDA or EMA); except where such noncompliance would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sanctions</U>. (i) The Company represents that, neither it nor any Subsidiary (collectively, the &ldquo;<U>Entity</U>&rdquo;)
nor, any director, officer, employee, nor to the Entity&rsquo;s knowledge, any agent, affiliate or representative of the Entity,
is a government, individual, or entity (in this paragraph (uu), &ldquo;<U>Covered Person</U>&rdquo;) that is, or is owned or controlled
by a Covered Person that is:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&nbsp;&nbsp;the
subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control
(&ldquo;<U>OFAC</U>&rdquo;), the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant
sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;), nor</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&nbsp;&nbsp;located,
organized or resident in a country or territory that is the subject of Sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 12pt; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;(ii)&nbsp;&nbsp;The
Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other Covered Person:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&nbsp;&nbsp;to
fund or facilitate any activities or business of or with any Covered Person or in any country or territory that, at the time of
such funding or facilitation, is the subject of Sanctions; or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&nbsp;&nbsp;in
any other manner that will result in a violation of Sanctions by any Covered Person (including any Covered Person participating
in the offering, whether as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 12pt; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;(iii)&nbsp;&nbsp;The
Entity represents and covenants that, except as detailed in the Prospectus, for the past 5 years, it has not knowingly engaged
in, is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Covered Person, or
in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Stock Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully
paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with in all material
respects.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>IT Systems</U>. (i)(x)There has been no security breach or attack or other compromise of or relating to any of the Company&rsquo;s
and its subsidiaries&rsquo; information technology and computer systems, networks, hardware, software, data (including the data
of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment
or technology (&ldquo;<U>IT Systems and Data</U>&rdquo;), and (y) the Company and its subsidiaries have not been notified of,
and have no knowledge of any event or condition that would reasonably be expected to result in any security breach, attack or
compromise to their IT Systems and Data, (ii) the Company and each of its subsidiaries have complied, and are presently in compliance
with, all applicable laws, statutes or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory
authority and all industry guidelines, standards, internal policies and contractual obligations relating to the privacy and security
of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification
and (iii) the Company and each of its subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>FINRA Exemption</U>. To enable the Agent to rely on Rule 5110(b)(7)(C)(i) of FINRA, the Company represents that the Company
(i) has a non-affiliate, public common equity float of at least $150 million or a non-affiliate, public common equity float of
at least $100 million and annual trading volume of at least three million shares and (ii) has been subject to the Exchange Act
reporting requirements for a period of at least 36 months.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or by the express
terms of this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to
the matters set forth therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Covenants of the Company</U>. The Company covenants and agrees with Agent that:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Registration Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating
to any Placement Shares is required to be delivered by Agent under the Securities Act (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act), (i)&nbsp;the Company will notify the Agent promptly of the time
when any subsequent amendment to the Registration Statement has been filed with the Commission and/or has become effective or
any subsequent supplement to the Prospectus has been filed and of any request by the Commission for any amendment or supplement
to the Registration Statement or Prospectus or for additional information related to the transactions contemplated by this Agreement,
(ii)&nbsp;the Company will prepare and file with the Commission, promptly upon the Agent&rsquo;s reasonable request, any amendments
or supplements to the Registration Statement or Prospectus that, in the Agent&rsquo;s reasonable opinion, may be necessary or
advisable in connection with the distribution of the Placement Shares by the Agent (provided, however, that the failure of the
Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&rsquo;s
right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the only
remedy the Agent shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement
until such amendment or supplement is filed); (iii)&nbsp;the Company will not file any amendment or supplement to the Registration
Statement or Prospectus, other than documents incorporated by reference, relating to the Placement Shares or a security convertible
into the Placement Shares unless a copy thereof has been submitted to Agent within a reasonable period of time before the filing
and the Agent has not reasonably objected thereto in writing within two (2) Business Days (provided, however, that (A) the failure
of the Agent to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&rsquo;s
right to rely on the representations and warranties made by the Company in this Agreement and (B) the Company has no obligation
to provide the Agent any advance copy of such filing or to provide Agent an opportunity to object to such filing if the filing
does not name the Agent or does not relate to the transactions contemplated by this Agreement; and provided, further, that the
only remedy Agent shall have with respect to the failure by the Company to obtain such consent shall be to cease making sales
under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a copy of any document that upon
filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for those documents available
via EDGAR; and (iv)&nbsp;the Company will cause each amendment or supplement to the Prospectus to be filed with the Commission
as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document to be incorporated
therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within the time period prescribed
(the determination to file or not file any amendment or supplement with the Commission under this Section 7(a), based on the Company&rsquo;s
reasonable opinion or reasonable objections, shall be made exclusively by the Company).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice of Commission Stop Orders</U>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge
thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the
initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts
to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will
advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or
any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to
the offering of the Placement Shares or for additional information related to the Registration Statement, the Prospectus or any
Issuer Free Writing Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Prospectus; Subsequent Changes</U>. During any period in which a Prospectus relating to the Placement Shares is
required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares, (including
in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), the Company will use
its commercially reasonable efforts to comply with all requirements imposed upon it by the Securities Act, as from time to time
in force, and to file on or before their respective due dates (taking into account any extensions available under the Exchange
Act) all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant
to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If the Company has omitted any information
from the Registration Statement pursuant to Rule 430B under the Securities Act, it will use commercially reasonable efforts to
comply with the provisions of and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the
Agent promptly of all such filings. If during such period any event occurs as a result of which the Prospectus as then amended
or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or
supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify Agent
to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration
Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance;
provided, however, that the Company may delay the filing of any amendment or supplement, if in the judgment of the Company, it
is in the best interests of the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Listing of Placement Shares</U>. During any period in which the Prospectus relating to the Placement Shares is required to
be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares, the Company will
use commercially reasonable efforts to cause the Placement Shares to be listed on the Exchange.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Registration Statement and Prospectus</U>. The Company will furnish to the Agent and its counsel (at the reasonable
expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference
therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during
any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including
all documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case
as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at Agent&rsquo;s
reasonable request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares
may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus) to
the Agent or its counsel to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Earnings Statement</U>. The Company will make generally available to its security holders as soon as practicable, but in any
event not later than 15 months after the end of the Company&rsquo;s current fiscal quarter, an earnings statement covering a 12-month
period that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act, provided that
the Company will be deemed to have furnished such statements to its security holders to the extent they are filed with the Commission
on EDGAR.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Use of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use
of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice of Other Sales</U>. Without prior written notice to Agent, the Company will not, (A) directly or indirectly, offer to
sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares
offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to
purchase or acquire, Common Stock during the period beginning on the date on which any Placement Notice is delivered to Agent
hereunder and ending on the second (2<SUP>nd</SUP>) Trading Day immediately following the final Settlement Date with respect to
Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to
the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); provided, however,
that such restrictions will not apply in connection with the Company&rsquo;s issuance, grant or sale of (i)&nbsp;Common Stock,
restricted stock units, options to purchase Common Stock or Common Stock issuable upon the exercise of options, or the vesting
of any of the foregoing, pursuant to any stock option or benefits plan, stock ownership plan or dividend reinvestment plan (but
not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect
or hereafter implemented, (ii)&nbsp;Common Stock issuable upon conversion of securities or the exercise of warrants, options,
convertible notes or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise
in writing to the Agent and (iii) Common Stock or securities convertible into or exchangeable for shares of Common Stock issued
in privately negotiated transactions to vendors, customers or other commercial or strategic partners or potential commercial or
strategic partners, as consideration for mergers, acquisitions, other business combinations or strategic alliances occurring after
the date of this Agreement which are not issued for capital raising purposes and (B) directly or indirectly in any other continuous
&ldquo;at the market&rdquo; offering similar to the continuous offering contemplated by this Agreement to sell, sell, contract
to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant to
this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire,
Common Stock prior to the termination of this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Change of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice advise the Agent promptly
after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any
material respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Due Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review conducted by the Agent or
its representatives in connection with the transactions contemplated hereby, including, without limitation, providing information
and making available documents and senior corporate officers, during regular business hours and at the Company&rsquo;s principal
offices, as the Agent may reasonably request, all upon reasonable advance notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Required Filings Relating to Placement of Placement Shares</U>. The Company agrees that on such dates as the Securities Act
shall require with respect to the Placement Shares, the Company will (i)&nbsp;file a prospectus supplement with the Commission
under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing under Rule 424(b), a &ldquo;<U>Filing
Date</U>&rdquo;), which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold
through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such
Placement Shares, and (ii)&nbsp;deliver such number of copies of each such prospectus supplement to each exchange or market on
which such sales were effected as may be required by the rules or regulations of such exchange or market.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representation Dates; Certificate</U>. On or prior to the date of the first Placement Notice delivered by the Company to the
Agent (such date, the &ldquo;<U>First Placement Date</U>&rdquo;) and each time the Company:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement
Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment,
sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus
relating to the Placement Shares;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information
or a material amendment to the previously filed Form 10-K);</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
files a quarterly report on Form 10-Q under the Exchange Act; or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
files a current report on Form 8-K containing amended financial information (other than information &ldquo;furnished&rdquo; pursuant
to Items 2.02 or 7.01 of Form&nbsp;8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification
of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under
the Exchange Act;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(each
date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &ldquo;<U>Representation Date.</U>&rdquo;)</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information
contained in such Form 8-K is material) with a certificate dated the Representation Date, in the form attached hereto as Exhibit
7(l). The requirement to provide a certificate under this Section 7(l) shall be waived for any Representation Date occurring at
a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company
delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next
occurring Representation Date; provided, however, that such waiver shall not apply for any Representation Date on which the Company
files its annual report on Form 10-K. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares
following a Representation Date when the Company relied on such waiver and did not provide the Agent with a certificate under
this Section 7(l), then before the Company delivers the Placement Notice or the Agent sells any Placement Shares, the Company
shall provide the Agent with a certificate, in the form attached hereto as Exhibit 7(l), dated the date of the Placement Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Legal Opinion and Negative Assurance Letter</U>. (1) On or before the First Placement Date, the Company shall cause to be furnished
to the Agent a written opinion and negative assurance letter of Haynes and Boone, LLP (&ldquo;<U>Company Counsel</U>&rdquo;),
or other counsel reasonably satisfactory to the Agent, each in form and substance reasonably satisfactory to Agent and its counsel;
and (2) within five (5) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate
in the form attached hereto as Exhibit 7(l) for which no waiver is applicable, the Company shall cause to be furnished to the
Agent a negative assurance letter of Company Counsel, or other counsel reasonably satisfactory to the Agent, in form and substance
reasonably satisfactory to Agent and its counsel; <I>provided</I>, <I>however</I>, the Company shall not be required to furnish
any such letter if the Company does not intend to deliver a Placement Notice in such calendar quarter until such time as the Company
delivers its next Placement Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Comfort Letter</U>. (1) On or before the First Placement Date and (2) within five (5) Trading Days of each Representation Date,
other than pursuant to Section 7(l)(iii), with respect to which the Company is obligated to deliver a certificate in the form
attached hereto as Exhibit 7(l) for which no waiver is applicable, the Company shall cause its independent accountants to furnish
the Agent letters (the &ldquo;<U>Comfort Letters</U>&rdquo;), dated the date the Comfort Letter is delivered, which shall meet
the requirements set forth in this Section 7(n). The Comfort Letter from the Company&rsquo;s independent accountants shall be
in a form and substance reasonably satisfactory to the Agent, (i) confirming that they are an independent public accounting firm
within the meaning of the Securities Act and the Public Company Account Oversight Board, (ii) stating, as of such date, the conclusions
and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&rsquo;
&ldquo;comfort letters&rdquo; to underwriters in connection with registered public offerings (the first such letter, the &ldquo;<U>Initial
Comfort Letter</U>&rdquo;) and (iii) updating the Initial Comfort Letter with any information that would have been included in
the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and
the Prospectus, as amended and supplemented to the date of such letter.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Market Activities</U>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to cause or result in,
or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security
of the Company to facilitate the sale or resale of Common Stock or (ii)&nbsp;sell, bid for, or purchase Common Stock in violation
of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent; provided,
however, that the Company may bid for and purchase shares of its Common Stock in accordance with Rule 10b-18 under the Exchange
Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Investment Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it
nor the Subsidiaries will be or become, at any time prior to the termination of this Agreement, an &ldquo;investment company,&rdquo;
as such term is defined in the Investment Company Act, <FONT STYLE="background-color: white">assuming no change in the Commission&rsquo;s
current interpretation as to entities that are not considered an investment company</FONT>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Offer to Sell</U>. Other than the Prospectus and the Issuer Free Writing Prospectus approved in advance by the Company and
the Agent in its capacity as agent hereunder, neither the Agent nor the Company (including its agents and representatives, other
than the Agent in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as
defined in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or
solicitation of an offer to buy Placement Shares hereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Blue Sky and Other Qualifications</U><I>. </I> The Company will use its commercially reasonable efforts, in cooperation with
the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered
and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate
and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares
(but in no event for less than one year from the date of this Agreement); <I>provided</I>, <I>however</I>, that the Company shall
not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction
in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt,
the Company will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification
or exemption, as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event
for less than one year from the date of this Agreement).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sarbanes-Oxley Act</U>. <FONT STYLE="background-color: white">The Company will maintain and keep accurate books and records
reflecting its assets and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles and including those policies and procedures that (i) pertain to the maintenance of records that
in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide
reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company's financial statements
in accordance with generally accepted accounting principles, (iii) that receipts and expenditures of the Company are being made
only in accordance with management's and the Company&rsquo;s directors&rsquo; authorization, and (iv) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have
a material effect on its financial statements. The Company will maintain such controls and other procedures, including, without
limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that are
designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and
forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by
the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management,
including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure and to ensure that material information relating to the Company is made
known to it by others within the organization, particularly during the period in which such periodic reports are being prepared.</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Payment of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations under this Agreement,
including (i) the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement
(including financial statements and exhibits) as originally filed and of each amendment and supplement thereto, in such number
as the Agent shall reasonably deem necessary, (ii) the printing and delivery to the Agent of this Agreement and such other documents
as may be required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii) the fees
and disbursements of the counsel, accountants and other advisors to the Company, (iv) the reasonable and documented out-of-pocket
expenses of Agent, including reasonable and documented fees and disbursements of counsel to the Agent incurred in connection with
(a) entering into the transactions contemplated by this Agreement in an amount not to exceed $50,000 in the aggregate, and (b)
ongoing diligence arising from the transactions contemplated by this Agreement in an amount not to exceed $10,000 in the aggregate
per calendar year; (v) the printing and delivery to the Agent of copies of any Permitted Issuer Free Writing Prospectus (defined
below) and the Prospectus and any amendments or supplements thereto in such number as the Agent shall deem reasonably necessary,
(vi) the preparation, printing and delivery to the Agent of copies of the blue sky survey, (vii) the documented fees and expenses
of the transfer agent and registrar for the Common Stock, (viii) the reasonable and documented fees and expenses incident to any
review by FINRA of the terms of the sale of the Placement Shares, including fees and expenses of counsel to the Agent, and (ix)
the documented fees and expenses incurred in connection with the listing of the Placement Shares on the Exchange.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Conditions to the Agent&rsquo;s Obligations</U>. The obligations of the Agent hereunder with respect to a Placement will be
subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due
performance by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory
to it in its reasonable judgment, and to the continuing reasonable satisfaction (or waiver by the Agent in its sole discretion)
of the following additional conditions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Registration Statement Effective</U>. The Registration Statement shall have become effective and shall be available for the
sale of all Placement Shares contemplated to be issued by any Placement Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Material Notices</U>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt by the Company
of any request for additional information from the Commission or any other federal or state governmental authority during the
period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements
to the Registration Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for
that purpose; (iii)&nbsp;receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding
for such purpose; or (iv)&nbsp;the occurrence of any event that makes any statement of material fact made in the Registration
Statement or the Prospectus or any material document incorporated or deemed to be incorporated therein by reference untrue in
any material respect or that requires the making of any changes in the Registration Statement, the Prospectus or Incorporated
Documents so that, in the case of the Registration Statement, it will not contain any materially untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading
and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Misstatement or Material Omission</U>. The Agent shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&rsquo;s reasonable opinion, in
consultation with outside counsel, is material, or omits to state a fact that in the Agent&rsquo;s reasonable opinion is material
and is required to be stated therein or is necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Material Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s reports filed with the
Commission, there shall not have been any Material Adverse Effect, or any development that would reasonably be expected to cause
a Material Adverse Effect, or a downgrading in or withdrawal of the rating assigned to any of the Company&rsquo;s securities (other
than asset backed securities) by any rating organization or a public announcement by any rating organization that it has under
surveillance or review its rating of any of the Company's securities (other than asset backed securities), the effect of which,
in the case of any such action by a rating organization described above, in the reasonable judgment of the Agent (without relieving
the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to
proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Legal Opinion</U>. The Agent shall have received the opinion and the negative assurance letter of Company Counsel required
to be delivered pursuant to Section 7(m) on or before the date on which such delivery of such opinion and letter, as applicable,
is required pursuant to Section 7(m).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Comfort Letter</U>. The Agent shall have received the Comfort Letter required to be delivered pursuant to Section 7(n) on or
before the date on which such delivery of such Comfort Letter is required pursuant to Section 7(n).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representation Certificate</U>. The Agent shall have received the certificate required to be delivered pursuant to Section
7(l) on or before the date on which delivery of such certificate is required pursuant to Section 7(l).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Secretary&rsquo;s Certificate</U>. On or prior to the first Representation Date, the Agent shall have received a certificate,
signed on behalf of the Company by its corporate Secretary, in form and substance satisfactory to the Agent and its counsel.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Suspension</U>. Trading in the Common Stock shall not have been suspended on the Exchange, and the Common Stock shall not
have been delisted from the Exchange.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Other Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company
shall have furnished to the Agent such appropriate further information, certificates and documents as the Agent may reasonably
request. All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company
will furnish the Agent with such conformed copies of such opinions, certificates, letters and other documents as the Agent shall
reasonably request.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Securities Act Filings Made</U>. All filings with the Commission required by Rule 424 under the Securities Act with respect
to the Placement Shares to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within
the applicable time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Approval for Listing</U>. The Placement Shares shall either have been approved for listing on the Exchange, subject only to
notice of issuance, or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or
prior to, the issuance of any Placement Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>FINRA</U>. FINRA shall have raised no objection to the terms of this offering and the amount of compensation allowable or payable
to the Agent as described in the Prospectus.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Termination Event</U>. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant
to Section 12(a).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Indemnification and Contribution</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Company Indemnification</U>. The Company agrees to indemnify and hold harmless the Agent, its partners, members, directors,
officers, employees and agents and each person, if any, who controls the Agent within the meaning of Section&nbsp;15 of the Securities
Act or Section&nbsp;20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based
upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment
thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included
in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the
aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body,
commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue
statement or omission; provided that (subject to Section&nbsp;10(d) below) any such settlement is effected with the written consent
of the Company, which consent shall not unreasonably be delayed or withheld; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
against any and all expense whatsoever, as incurred (including the reasonable and documented fees and disbursements of counsel),
reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any
governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission,
or any such alleged untrue statement or omission, of the Company to the extent that any such expense is not paid under (i)&nbsp;or
(ii)&nbsp;above,</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U>,
<U>however</U>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity
with written information furnished to the Company by the Agent expressly for use in the Registration Statement (or any amendment
thereto), or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Agent Indemnification</U>. Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the
Company who signed the Registration Statement, and each person, if any, who (i)&nbsp;controls the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii)&nbsp;is controlled by or is under common control with
the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 10(a),
as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration
Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity
with information relating to the Agent and furnished to the Company in writing by the Agent expressly for use therein.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Procedure</U>. Any party that proposes to assert the right to be indemnified under this Section 10 will, promptly after receipt
of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party
or parties under this Section 10, notify each such indemnifying party of the commencement of such action, enclosing a copy of
all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any
liability that it may have to any indemnified party otherwise than under this Section 10 and (ii)&nbsp;any liability that it may
have to any indemnified party under the foregoing provision of this Section 10 unless, and only to the extent that, such omission
results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any
indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate
in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of
the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume
the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying
party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified
party for any legal or other expenses except as provided below and except for the reasonable and documented costs of investigation
subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ
its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified
party unless (1)&nbsp;the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party,
(2)&nbsp;the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available
to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3)&nbsp;a
conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and
the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf
of the indemnified party) or (4)&nbsp;the indemnifying party has not in fact employed counsel to assume the defense of such action
within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable and documented
fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood
that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such
jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be
reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice related to fees, disbursements
and other reasonable charges in detail. An indemnifying party will not, in any event, be liable for any settlement of any action
or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified
party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating
to the matters contemplated by this Section 10 (whether or not any indemnified party is a party thereto), unless such settlement,
compromise or consent (1)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such
litigation, investigation, proceeding or claim and (2)&nbsp;does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Contribution</U>. In order to provide for just and equitable contribution in circumstances in which the indemnification provided
for in the foregoing paragraphs of this Section 10 is applicable in accordance with its terms but for any reason is held to be
unavailable from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities,
expenses and damages (including any investigative, legal and other expenses reasonably incurred and documented in connection with,
and any amount paid in settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution
received by the Company from persons other than the Agent, such as persons who control the Company within the meaning of the Securities
Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution)
to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits
received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the
one hand and the Agent on the other hand shall be deemed to be in the same proportion as the total net proceeds from the sale
of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent
(before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided
by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault
of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in
such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations
with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue
or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions
pursuant to this Section 10(d) were to be determined by pro rata allocation or by any other method of allocation that does not
take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result
of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 10(d) shall
be deemed to include, for the purpose of this Section 10(d), any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim to the extent consistent with Section 10(c) hereof.
Notwithstanding the foregoing provisions of this Section 10(d), the Agent shall not be required to contribute any amount in excess
of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section 10(d), any person who controls a party to this Agreement within the meaning of
the Securities Act, and any officers, directors, partners, employees or agents of the Agent, will have the same rights to contribution
as that party, and each director of the Company and each officer of the Company who signed the Registration Statement will have
the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution
may be made under this Section 10(d), will notify any such party or parties from whom contribution may be sought, but the omission
to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they
may have under this Section 10(d) except to the extent that the failure to so notify such other party materially prejudiced the
substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to
the last sentence of Section 10(c) hereof, no party will be liable for contribution with respect to any action or claim settled
without its written consent if such consent is required pursuant to Section 10(c) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Additional Covenants</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Covenants of the Agent</U>. The Agent represents and warrants that it is duly registered as a broker-dealer
under FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be
offered and sold, except such states in which the Agent is exempt from registration or such registration is not otherwise required.
The Agent shall continue, for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act
and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such
states in which the Agent is exempt from registration or such registration is not otherwise required, during the term of this
Agreement. The Agent shall comply with all applicable law and regulations in connection with the transactions contemplated by
this Agreement, including the issuance and sale through the Agent of the Placement Shares</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in Section 10 of
this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall
survive, as of their respective dates, regardless of (i)&nbsp;any investigation made by or on behalf of the Agent, any controlling
persons, or the Company (or any of their respective officers, directors or controlling persons), (ii)&nbsp;delivery and acceptance
of the Placement Shares and payment therefor or (iii)&nbsp;any termination of this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Agent may terminate this Agreement, by written notice to the Company, as hereinafter specified at any time (1)&nbsp;if there
has been, since the time of execution of this Agreement or since the date as of which information is given in the Prospectus,
any Material Adverse Effect, or any development that would reasonably be expected to result in a Material Adverse Effect has occurred,
which in the reasonable judgment of the Agent, is material and adverse and makes it impractical or inadvisable to market the Placement
Shares, (2)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development
involving a prospective change in national or international political, financial or economic conditions, in each case the effect
of which is such as to make it, in the judgment of the Agent, impracticable or inadvisable to market the Placement Shares or to
enforce contracts for the sale of the Placement Shares, (3)&nbsp;if trading in the Common Stock has been suspended or limited
by the Commission or the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum prices for
trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company on any exchange or
in the over-the-counter market shall have occurred and be continuing, (5) if a major disruption of securities settlements or clearance
services in the United States shall have occurred and be continuing, or (6)&nbsp;if a banking moratorium has been declared by
either U.S. Federal or New York authorities. Any such termination shall be without liability of any party to any other party except
that the provisions of Section 8 (Expenses), Section 10 (Indemnification), Section 11 (Survival of Representations), Section 17
(Governing Law; Consent to Jurisdiction) and Section 18 (Waiver of Jury Trial) hereof shall remain in full force and effect notwithstanding
such termination. If the Agent elects to terminate this Agreement as provided in this Section 12(a), the Agent shall provide the
required written notice as specified in Section 13 (Notices).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company shall have the right, by giving ten (10) days written notice as hereinafter specified to terminate this Agreement
in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party
to any other party except that the provisions of Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain
in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Agent shall have the right, by giving ten (10) days written notice as hereinafter specified to terminate this Agreement in
its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party
to any other party except that the provisions of Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain
in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unless earlier terminated pursuant to this Section 12, this Agreement shall automatically terminate upon the issuance and sale
of all of the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; provided that the
provisions of Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain in full force and effect notwithstanding
such termination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Agreement shall remain in full force and effect unless terminated pursuant to Sections 12(a), (b), (c), or (d) above or otherwise
by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed
to provide that Section 8, Section 10, Section 11, Section 17 and Section 18 shall remain in full force and effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that
such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the
Company, as the case may be; provided, further, any termination of this Agreement in accordance with the terms of Section 12(b)
or (c) shall not be effective until the date that is ten days after the date of such written notice. If such termination shall
occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the
provisions of this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Subject to the additional limitations set forth in Section 8 of this Agreement, in the event of termination of this Agreement
prior to the sale of any Placement Shares, the Agent shall be entitled only to reimbursement of its out-of-pocket expenses actually
incurred.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. All notices or other communications required or permitted to be given by any party to any other party pursuant
to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall be delivered to:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JonesTrading
Institutional Services LLC</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">900
Island Park Drive, Suite 160</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
Island, SC 29492</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Burke Cook</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
burke@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duane
Morris, LLP</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1540
Broadway</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10036&#9;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Dean M. Colucci</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
DMColucci@duanemorris.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
if to the Company, shall be delivered to:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Madison Avenue, 7<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10016</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Steve O&rsquo;Loughlin</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
soloughlin@actinium.com&#9;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haynes
and Boone, LLP</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30
Rockefeller Plaza, 26th Floor</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10012</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Rick A. Werner, Esq.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
rick.werner@haynesboone.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new
address for such purpose. Each such notice or other communication shall be deemed given (i)&nbsp;when delivered personally or
by verifiable facsimile transmission (with an original to follow) on or before 4:30&nbsp;p.m., New York City time, on a Business
Day (as defined below) or, if such day is not a Business Day, on the next succeeding Business Day, (ii)&nbsp;on the next Business
Day after timely delivery to a nationally-recognized overnight courier and (iii)&nbsp;on the Business Day actually received if
deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
electronic communication (&ldquo;<U>Electronic Notice</U>&rdquo;) shall be deemed written notice for purposes of this Section
13 if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed
received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving
Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<U>Nonelectronic
Notic</U>e&rdquo;) which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic
Notice.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and
their respective successors and the affiliates, controlling persons, officers and directors referred to in Section 10 hereof.
References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of
such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement
without the prior written consent of the other party; provided, however, that the Agent may assign its rights and obligations
hereunder to an affiliate thereof without obtaining the Company&rsquo;s consent, so long as such affiliate is a registered broker
dealer.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Adjustments for Stock Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement
shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Placement
Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Entire Agreement; Amendment; Severability</U>. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements
and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement
nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event
that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal
or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to
the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall
be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that
giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of
the parties as reflected in this Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK
CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL
BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>CONSENT TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL
COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH
ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING,
ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT
IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES
PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF
(CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT
AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN
SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Use of Information</U>.&#9;The Agent may not use any information gained in connection with this Agreement and the transactions
contemplated by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved
by the Company.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other
may be made by facsimile or other electronic transmission.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Effect of Headings</U>. The section and Exhibit&nbsp;headings herein are for convenience only and shall not affect the construction
hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Permitted Free Writing Prospectuses</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents, warrants and agrees that, unless it obtains the prior consent of the Agent (which consent shall not be unreasonably
withheld or delayed), and the Agent represents, warrants and agrees that, unless it obtains the prior consent of the Company,
it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus,
or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule&nbsp;405, required to be filed
with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case may be (a &ldquo;<U>Permitted
Free Writing Prospectus</U>&rdquo;). The Company represents and warrants that it has treated and agrees that it will treat each
Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, and has complied
and will comply with the requirements of Rule&nbsp;433 applicable to any Permitted Free Writing Prospectus, including timely filing
with the Commission where required, legending and record keeping.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Absence of Fiduciary Relationship</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;The
Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each
transaction contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship
between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any
other party, on the one hand, and the Agent, on the other hand, has been or will be created in respect of any of the transactions
contemplated by this Agreement, irrespective of whether or not the Agent has advised or is advising the Company on other matters,
and the Agent has no obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations
expressly set forth in this Agreement;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions
contemplated by this Agreement;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this
Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and the Agent has no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship or otherwise; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
it waives, to the fullest extent permitted by law, any claims it may have against the Agent for breach of fiduciary duty or alleged
breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agent shall
not have any liability (whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty
claim or to any person asserting a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors
of Company, other than in respect of the Agent&rsquo;s obligations under this Agreement and to keep information provided by the
Company to the Agent and the Agent&rsquo;s counsel confidential to the extent not otherwise publicly-available.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions</U>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the following terms have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Time</U>&rdquo; means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement,
and (iii) each Settlement Date.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, relating
to the Placement Shares that (1)&nbsp;is required to be filed with the Commission by the Company, (2)&nbsp;is a &ldquo;road show&rdquo;
that is a &ldquo;written communication&rdquo; within the meaning of Rule&nbsp;433(d)(8)(i) whether or not required to be filed
with the Commission, or (3)&nbsp;is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i) because it contains a description of
the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be
filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule
433(g) under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
172</U>,&rdquo; &ldquo;<U>Rule 405</U>,&rdquo; &ldquo;<U>Rule 415</U>,&rdquo; &ldquo;<U>Rule 424</U>,&rdquo; &ldquo;<U>Rule&nbsp;424(b)</U>,&rdquo;
&ldquo;<U>Rule&nbsp;430B</U>,&rdquo; and &ldquo;<U>Rule&nbsp;433</U>&rdquo; refer to such rules under the Securities Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company that may be identified on Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K for
the most recently ended fiscal year, and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means any day on which shares of Common Stock are purchased and sold on the Exchange.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to financial statements and schedules and other information that is &ldquo;contained,&rdquo; &ldquo;included&rdquo;
or &ldquo;stated&rdquo; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information that is incorporated by reference in the
Registration Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing
shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer
Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule&nbsp;433, are not required to
be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all
references in this Agreement to &ldquo;supplements&rdquo; to the Prospectus shall include, without limitation, any supplements,
&ldquo;wrappers&rdquo; or similar materials prepared in connection with any offering, sale or private placement of any Placement
Shares by the Agent outside of the United States.</FONT></P>




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 2in; text-align: left; text-indent: 80pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 2in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
    PHARMACEUTICALS, INC. </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-left: 0; width: 1%; padding-right: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ACCEPTED
as of the date first-above written:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>JONESTRADING
INSTITUTIONAL SERVICES LLC</B></FONT></P>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-left: 0; padding-right: 0; text-align: justify; text-indent: 0; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Burke Cooke</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Burke Cooke</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.75pt"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
                                         General Counsel</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>



<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
1</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF PLACEMENT NOTICE</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:
&#9;ACTINIUM PHARMACEUTICALS, INC.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JONESTRADING
                                         INSTITUTIONAL SERVICES LLC<BR>
                                         Attention: _____________________</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:
&#9;Placement Notice</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#9;[&bull;]</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the Capital on Demand<B>&trade;</B> Sales Agreement between Actinium Pharmaceuticals,
Inc. (the &ldquo;<U>Company</U>&rdquo;) and JONESTRADING INSTITUTIONAL SERVICES LLC (&ldquo;<U>Agent</U>&rdquo;), dated August
7, 2020, the Company hereby requests that the Agent sell up to ____________ of the Company&rsquo;s Common Stock, $0.001 par value
per share, at a minimum market price of $_______ per share, during the time period beginning [month, day, time] and ending [month,
day, time].</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
2</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3.0%
of the gross proceeds from each sale of Placement Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
3</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
Parties</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Company</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
Seth&#9; sseth@actiniumpharma.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O&rsquo;Loughlin&#9; soloughlin@actiniumpharma.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
Siegel&#9; gsiegel@actiniumpharma.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Agent</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moe
Cohen &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
moec@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bryan
Turley &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
bturley@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
D&rsquo;Agostini &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; johnd@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
Gerety &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ryang@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Burke
Cook &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
burke@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
Loforte rloforte@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to JTCM@jonestrading.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
7(l)</U></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Representation Date Certificate</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>____________________,
20__</B><BR>
<BR></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Representation Date Certificate (this &ldquo;<U>Certificate</U>&rdquo;) is executed and delivered in connection with Section 7(l)
of the Capital on Demand<B>&trade;</B> Sales Agreement (the &ldquo;<U>Agreement</U>&rdquo;), dated August 7, 2020, and entered
into between Actinium Pharmaceuticals, Inc. (the &ldquo;<U>Company</U>&rdquo;) and JonesTrading Institutional Services LLC. All
capitalized terms used but not defined herein shall have the meanings given to such terms in the Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, a duly appointed and authorized officer of the Company, having made all necessary inquiries to establish the accuracy
of the statements below and having been authorized by the Company to execute this certificate, hereby certifies as follows:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this Certificate, (i) the Registration Statement does not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and
(ii) neither the Registration Statement nor the Prospectus contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein not untrue or misleading.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the representations and warranties of the Company contained in the Agreement (<FONT STYLE="background-color: white">A) to the
extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality
or Material Adverse Effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made
on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which
were true and correct as of such date, and (B) to the extent such representations and warranties are not subject to any qualifications
or exceptions, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with
the same force and effect as if expressly made on and as of the date hereof except for those representations and warranties that
speak solely as of a specific date and which were so true and correct as of such date; and</FONT>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the covenants required to be performed by the Company in the Agreement on or prior to the date of the Agreement, this Representation
Date, and each such other date as set forth in the Agreement, has been duly, timely and fully performed in all material respects
and each condition required to be complied with by the Company on or prior to the date of the Agreement, this Representation Date,
and each such other date as set forth in the Agreement has been duly, timely and fully complied with in all material respects.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
to the date of the most recent financial statements in the Prospectus, there has been no Material Adverse Effect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and no proceedings
for that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including,
without limitation, the Commission).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
order suspending the effectiveness of the Registration Statement or the qualification or registration of the Placement Shares
under the applicable securities or blue sky laws of any applicable jurisdiction are in effect and no proceeding for such purpose
is pending before, or threatened, to the Company's knowledge or in writing by, any applicable securities or other governmental
authority (including, without limitation, the Commission).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned has executed this Representation Date Certificate as of the date first written above.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 50%; padding-right: 2.85pt; padding-left: 2.85pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
    PHARMACEUTICALS, INC. </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 2.85pt; padding-left: 2.85pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:<U>&#9;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 2.85pt; padding-left: 2.85pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;_________________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 2.85pt; padding-left: 2.85pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    ___________________________________</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea125182ex5-1_actinium.htm
<DESCRIPTION>OPINION OF HAYNES AND BOONE LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex5-1_01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right">August 7, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">275 Madison Avenue, 7<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as counsel
for Actinium Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the filing
with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on the date hereof, under the Securities
Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;), of a registration statement on Form S-3 (the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;) by the Company relating to (a) shares of common stock, par value $0.001 per share, of the Company (the
&ldquo;<B><I>Common Stock</I></B>&rdquo;), (b) shares of preferred stock, par value $0.001 per share, of the Company (the &ldquo;<B><I>Preferred
Stock</I></B>&rdquo;), (c) warrants to purchase Common Stock or Preferred Stock (the &ldquo;<B><I>Warrants</I></B>&rdquo;), (d)
subscription rights to purchase shares of Common Stock or other securities offered in the Registration Statement (the &ldquo;<B><I>Subscription
Rights</I></B>&rdquo;), and (e) units consisting of any combination of Common Stock, Preferred Stock, Warrants, or Subscription
Rights (the &ldquo;<B><I>Units</I></B>&rdquo; and, together with the Common Stock, the Preferred Stock, the Warrants, and the Subscription
Rights, the &ldquo;<B><I>Securities</I></B>&rdquo; and each individually, a &ldquo;<B><I>Security</I></B>&rdquo;) that may be issued
and sold from time to time pursuant to Rule 415 under the Act for an aggregate initial offering price not to exceed $500,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We also have acted
as counsel to the Company in connection with an offering of up to $200,000,000 of shares of Common Stock that may be issued and
sold (the &ldquo;<B><I>Sales Agreement Shares</I></B>&rdquo;) under a Capital on Demand&trade; Sales Agreement executed by the
Company and JonesTrading Institutional Services LLC on August 7, 2020 (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;). The
prospectus for the offer and sale of the Sales Agreement Shares is included in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of the
opinions we express below, we have examined originals, or copies certified or otherwise identified, of (i) the certificate of incorporation
and the amended and restated bylaws, each as amended to date, of the Company (the &ldquo;<B><I>Company Charter Documents</I></B>&rdquo;);
(ii) the base prospectus for the offer and sale of the Securities (as may be amended or supplement, the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;);
(iii) the specimen Common Stock certificate of the Company, (iv) the form of Sales Agreement, and (v) such other corporate records
of the Company as we have deemed necessary or appropriate for purposes of the opinions hereafter expressed.&nbsp; In addition,
we have reviewed certain certificates of officers of the Company and of public officials, and we have relied on such certificates
with respect to certain factual matters that we have not independently established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As to questions of
fact material to the opinions expressed below, we have, without independent verification of their accuracy, relied to the extent
we deem reasonably appropriate upon the representations and warranties of the Company contained in such documents, records, certificates,
instruments or representations furnished or made available to us by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In making the foregoing
examination, we have assumed (i) the genuineness of all signatures, (ii) the authenticity of all documents submitted to us as originals,
(iii) the conformity to original documents of all documents submitted to us as certified or photostatic copies, (iv) that all agreements
or instruments we have examined are the valid, binding and enforceable obligations of the parties thereto, and (v) that all factual
information on which we have relied was accurate and complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Haynes and Boone, LLP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Attorneys and Counselors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">30 Rockefeller Plaza<BR>
26th Floor<BR>
New York, New York 10112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T (212) 659-7300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F (212) 918-8989</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">www.haynesboone.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">August 7, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">With respect to the
Securities, we have also assumed that (i) the Company will continue to be incorporated and in existence and good standing in its
jurisdiction of organization, (ii) the Registration Statement, and any amendments thereto (including post-effective amendments),
will have become effective; (iii) no stop order of the Commission preventing or suspending the use of the Base Prospectus contained
in the Registration Statement or any prospectus supplement will have been issued; (iv) a prospectus supplement will have been prepared
and filed with the Commission properly describing the Securities offered thereby and will have been delivered to the purchaser(s)
of the Securities as required in accordance with applicable law; (v) all Securities will be offered, issued and sold in compliance
with applicable federal and state securities laws and in the manner stated in the Registration Statement and the appropriate prospectus
supplement; (vi) a definitive purchase, underwriting or similar agreement with respect to any Securities offered will have been
duly authorized and validly executed and delivered by the Company and the other parties thereto and will be an enforceable obligation
of the parties thereto; (vii) in connection with the sale of Warrants, any required warrant agreement or agreement relating to
the Warrants (a &ldquo;<B><I>Warrant Agreement</I></B>&rdquo;) will have been executed and delivered by all applicable parties
and will be enforceable in all respects in accordance with its terms; (viii) in connection with the sale of Units, any required
unit agreement or agreement relating to the Units (a &ldquo;<B><I>Unit Agreement</I></B>&rdquo;) will have been executed and delivered
by all applicable parties and will be enforceable in all respects in accordance with its terms; (ix) in connection with the sale
of Subscription Rights, any required subscription rights agreement or agreement relating to the Subscription Rights (a &ldquo;<B><I>Subscription
Rights Agreement</I></B>&rdquo;) will have been executed and delivered by all applicable parties and will be enforceable in all
respects in accordance with its terms; (x) any securities issuable upon conversion, exchange, redemption or exercise of any Securities
being offered will be duly and validly authorized, created and, if appropriate, reserved for issuance upon such conversion, exchange,
redemption or exercise; and (xi) with respect to shares of Common Stock, Preferred Stock, there will be sufficient shares of Common
Stock or Preferred Stock authorized under the Charter Documents and not otherwise reserved for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based on the foregoing,
and subject to the limitations and qualifications set forth herein, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">1.&nbsp;With respect to shares of Common Stock, when (i) the Board of Directors of the Company or, to the extent permitted by the Delaware
General Corporation Law (the &ldquo;<B><I>DGCL</I></B>&rdquo;) and the Charter Documents, a duly constituted and acting committee
thereof (such Board of Directors or committee being hereinafter referred to as the &ldquo;<B><I>Company Board</I></B>&rdquo;) has
taken all necessary corporate action to approve the issuance thereof and the terms of the offering of shares of Common Stock and
related matters, and (ii) certificates representing the shares of Common Stock have been duly executed, countersigned, registered
and delivered, or if uncertificated, valid book-entry notations have been made in the share register of the Company, in each case
in accordance with the provisions of the Charter Documents, either (a) in accordance with the applicable definitive purchase, underwriting
or similar agreement approved by the Company Board and upon payment of the consideration therefor (which shall not be less than
the par value of the Common Stock) provided for therein, all in accordance with the Registration Statement and any applicable prospectus
supplement, or (b) upon conversion, exchange, redemption or exercise of any other Security, in accordance with the terms of such
Security or the instrument governing such Security providing for such conversion, exchange, redemption or exercise as approved
by the Company Board, and for the consideration approved by the Company Board (which shall not be less than the par value of the
Common Stock), all in accordance with the Registration Statement and any applicable prospectus supplement, the shares of Common
Stock will be validly issued, fully paid and non-assessable. The Common Stock covered in the opinion in this paragraph includes
any shares of Common Stock that may be issued upon exercise, conversion or exchange pursuant to the terms of any other Securities
but does not include the Sales Agreement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">2.&nbsp;With respect to shares of Preferred Stock, when (i) the Company Board has taken all necessary corporate action to approve and establish
the terms of the shares of Preferred Stock, to approve the issuance thereof and the terms of the offering thereof and related matters,
including the adoption of a Certificate of Designations relating to such Preferred Stock (a &ldquo;<B><I>Certificate of Designations</I></B>&rdquo;),
and such Certificate of Designations has been filed with the Secretary of State of the State of Delaware, and (ii) certificates
representing the shares of Preferred Stock have been duly executed, countersigned, registered and delivered, or if uncertificated,
valid book-entry notations have been made in the share register of the Company, in each case in accordance with the provisions
of the Charter Documents, either (a) in accordance with the applicable definitive purchase, underwriting or similar agreement approved
by the Company Board and upon payment of the consideration therefor (which shall not be less than the par value of the Preferred
Stock) provided for therein, all in accordance with the Registration Statement and any applicable prospectus supplement, or (b)
upon conversion, exchange, redemption or exercise of any other Security, in accordance with the terms of such Security or the instrument
governing such Security providing for such conversion, exchange, redemption or exercise as approved by the Company Board, and for
the consideration approved by the Company Board (which shall not be less than the par value of the Preferred Stock), all in accordance
with the Registration Statement and any applicable prospectus supplement, the shares of Preferred Stock will be validly issued,
fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">August 7, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&#9;&#9;3.&#9;With
respect to the Warrants, when (i) the Company Board has taken all necessary corporate action to approve the creation of and the
issuance and terms of the Warrants, the terms of the offering thereof and related matters, (ii) the Warrant Agreements and Warrants
have been duly prepared, authorized and validly executed and delivered by the Company and the other parties thereto (if any) in
compliance with all applicable laws and (iii) the Warrants or certificates representing the Warrants have been duly registered
and delivered in accordance with the appropriate Warrant Agreements and the applicable definitive purchase, underwriting or similar
agreement approved by the Company Board and upon payment of the consideration therefor provided for therein (which shall not be
less than the par value of any Common Stock or Preferred Stock underlying such Warrants), all in accordance with the Registration
Statement and any prospectus supplement, the Warrants will constitute valid and legally binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&#9;4.&#9;With
respect to the Subscription Rights, when (i) the Company Board has taken all necessary corporate action to approve the creation
of and the issuance and terms of the Subscription Rights, the terms of the offering thereof and related matters, (ii) such Subscription
Rights and any Subscription Rights Agreement or agreements establishing such Subscription Rights and the rights of the holders
thereof have been duly authorized and prepared and validly executed and delivered by the Company and each other party thereto in
compliance with applicable laws and (iii) such Subscription Rights have been delivered in accordance with the applicable duly authorized
definitive purchase, underwriting or similar agreement approved by the Company Board and upon payment of the consideration therefor
provided for therein, the Subscription Rights will constitute valid and legally binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">5.&nbsp;With
respect to the Units, when (i) the Company Board has taken all necessary corporate action to approve the creation of and the issuance
and terms of the Units, the terms of the offering thereof and related matters, (ii) such Units and any Unit Agreement or agreements
establishing such Units and the rights of the holders thereof have been duly authorized and prepared and validly executed and delivered
by the Company and each other party thereto in compliance with applicable laws and (iii) such Units have been delivered in accordance
with the applicable duly authorized definitive purchase, underwriting or similar agreement approved by the Company Board and upon
payment of the consideration therefor provided for therein, the Units will constitute valid and legally binding obligations of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">6.&nbsp;The
Sales Agreement Shares are duly authorized and, when such shares have been issued and delivered against payment of the purchase
price therefor (in an amount in excess of the par value thereof) in accordance with the Sales Agreement, and as contemplated by
the Registration Statement, the Sales Agreement Shares will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The opinions set forth
above are subject to the following qualifications, limitations and exceptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(a) The opinions are
subject to (i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium, rearrangement, liquidation, conservatorship
or other similar laws now or hereafter in effect relating to or affecting the rights of creditors generally, (ii) provisions of
applicable law pertaining to the voidability of preferential or fraudulent transfers and conveyances and (iii) the fact that the
remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the
discretion of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">August 7, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(b) The opinions are
subject to the effect of (i) general principles of equity, including (without limitation) concepts of materiality, reasonableness,
good faith and fair dealing, general matters of public policy and other similar doctrines generally affecting the enforceability
of agreements (regardless of whether considered in a proceeding in equity or at law) (ii) obligations of good faith and fair dealing
under New York law and (iii) other commonly-recognized statutory and judicial constraints on enforceability, including statutes
of limitation, limitations on rights to indemnification that contravene law or public policy and the effectiveness of waivers of
rights or benefits that cannot be effectively waived under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(c) In rendering the
opinions, we have assumed that, at the time of the sale of the Securities, (i) the resolutions of the Board of Directors or similar
governing body, as reflected in the minutes and proceedings of the Company, will not have been modified or rescinded and (ii) there
will not have occurred any change in the laws affecting the authorization, execution, delivery, issuance, sale, ranking, validity
or enforceability of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The opinions expressed
herein are limited to the federal laws of the United States of America, and, to the extent relevant to the opinions expressed herein,
(i) the DGCL and (ii) the laws of the State of New York, in each case as in effect on the date hereof (all of the foregoing being
referred to as the &ldquo;<B><I>Opined on Law</I></B>&rdquo;). We do not express any opinion with respect to any other laws, or
the laws of any other jurisdiction (including, without limitation, any laws of any other jurisdiction which might be referenced
by the choice-of-law rules of the Opined on Law), other than the Opined on Law or as to the effect of any such other laws on the
opinions herein stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We hereby consent to
the filing of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to our firm contained therein under
the heading &ldquo;Legal Matters.&rdquo;&nbsp; In giving this consent, we do not hereby admit we are in the category of persons
whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">/s/ Haynes and Boone, LLP</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea125182ex23-1_actinium.htm
<DESCRIPTION>CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We consent to the incorporation by reference
in this Registration Statement of Actinium Pharmaceuticals, Inc. on Form S-3 of our report dated May 8, 2020, with respect to our
audits of the consolidated financial statements of Actinium Pharmaceuticals, Inc. as of December 31, 2019 and 2018 and for the
years ended December 31, 2019 and 2018 appearing in the Annual Report on Form 10-K of Actinium Pharmaceuticals, Inc. for the year
ended December 31, 2019. We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus,
which is part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 7, 2020</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "5 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH *:6 SW(&<#KBF-( ">@! ))'.>..2.O&3W[=#5&:Z52?F*@ \;N21SS^
M(&"3G&0HS@5482D[)$2FH+5_UY_\,6VD"#!(4<]#S[9)Q]3@8XQN]:KW:*3R
M% X[Y)R<'')SGKG( '6N?O-76(G#XP"3RO7!ZC/)X.?\" >-O_$T:9'F@ 9P
M P')PH^N>?E'I]*]'#Y=4J[1;VZ:?D>?7QU.DFY5$DO-)_/6W]=ST.34D7),
MBDY[G'?U' //'.>W7)JC)J\0'WP.3G/0'."?3@Y^IX^GC-[XP1 <2#OR6' !
M(!P#@>H^H[%17,3^-@NX"4XR.-PYZ\$'T)X'48(/4X]FCD%::3Y&O+E_6QXU
M?/\ #TV[U%_X%^=FE\CZ'.M0\CS.@X)(//&01@X(R, 8R.O2D_MN$8'F=0=Q
M! XZ<?*.23W/ Z@CFOF=O&_4^9UQG+#'&1S@YR<\D=?Y>:?$O]I[X2?!?2K+
M7?B]\4/!7PTTS4IY;?2[GQEXAL-&.K3Q*/.ATJUN9OMFIRP@J95L;:X\C<HE
MV%P&[:?"^*K24*=&I4D_AITX2FV[/1*$9-Z)O9^=CD_UDP[>E2*[M-?CK\S[
MICUB+/WUP3CZX/)X(XQU] 3QC.+T>I(Q!#@GGH<^A/7J<\\'TQP:^'OA7^TQ
M\)?C3H]SK_PD^)G@OXDZ-87"6FHWO@[7]/UH:9=2J6BM]4M[:5KO3)IE5FC2
M_M[<S*KF(.%)'MEGXS1MI,O/][<,C&,'KG/Z ?6N;$\.XK#RE"K0J4ZBNG"I
M3E"2=MG&236FNJZHZJ&?X>=ESK?2TK=5TO;^D?0L=XK$993D=<^@R23V[Y /
M0D]JMI,K<!@3CH3CGTSSSTX/<GG  KQ^P\2I+M_>$Y'/. 2< X.1GW&0?KGC
ML[36(Y /F ^8$<@C:.I/!(/(!(&",UX6(RZK2;O%JV]EI]Q[5#,:=5*TD[^:
MO\]=;_A]QV88'H<_UZ]/7H>F:6LN"Z#J"2#D@]1GD_>[9)&22,8'UQ6@K@X'
M!!XR.?P;W]^AKSI0E!VDK'H1G&6S)****DL0C.01QQCW_P *7('Z_I_*D(Y!
M].GXU\A?M)_M"MX!L[GP7X&F@N?'E[;[;N^VI<V?A"UN4)2[N8V#17.M3QMY
MFF:7("B*5O\ 45%F+>"^ZL%@ZV/Q-+#4$N>I))REI"$;I2G-VLHQ5VWN]HIM
MHX<PQ]'+<)6Q5>_+2@VH1UG4E9VA!;\TFDO*]^AYY^V+^UF?A9I]W\//AK<V
M]W\3=0M0+[4]L=U9> K&ZC#1ZA>1-NBNM?N8F671='E#1QKLU75$%@MK::KX
M_P#L1?MNW7BJ\M?@I\;=4/\ PG$$S:?X,\;ZB8;9?',$9(@TK6F18;>W\9)$
M%,<J1Q6_B1 7A1-6$D5[\5W'A/4=?U*Y>1KB]O;V>>]U/5+Z22ZN)I[F4RW6
MH:A=2%Y;FZN)7>1WD)FFD( ^4#;S?B#X,:'-<0O#_;SZI<7UO%9IIDC3ZEJ&
MJS2(EA;Z7:QP/.=0FNA&;..U)F67:T<B!/,3]_R_A3@V?#-;)<8HQS"K'ZTL
M[27UBAC(4W9ZR2^IKX)T&TI4[S;51*:_DS/>-N/Z'&N&XCP-2J\OHS6#7#_O
MO"XG 3JI3IN"B[XR6DX5^7GA4M%>Y>+_ *5BZ$9)RI&<\X(]<CCCOSQWIP(/
M0@_0@_RKP+]G^R^)^@_"KPQIGQAUF#6/&UI;-'=7485[Z*P+_P#$JLM>O89F
MMM3U^TM/+@UC5+-(K:\O [HMP^Z^N_;$N=_<$\<]\C'7OSG@@X!'Y_@.*P;P
MV(Q%"-6EB(4:U2G&O1<G1K1A.455IR:3<)I<T6TM_*[_ *OR['O'8#!XNIAZ
MN#J8G#TJT\+72C6P\ZE.$Y4JD5=*4')IZZZ;7:6E142.&Z=!U)/(/3G^]QU/
M;C/K4M<K33LST4TU=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MUE.-V]'%2N^R6NNUDKW^\M9/''KGGIZ?7-&.0?3./QKS7PQ\7_AGXR\8>+/
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M2#R3UP:ZW5+D11N=V/E;(X'(&,]1T. 1@8.<9 ->"^,-7\L2 .!R1P?8YQG
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MEU'VFDZ;QM=N$]I1]Z*NDWHUHT?MWK7Q?^%\R.+;XD^!9]V['D^+-#?)P0
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M?$+TI0?Z_P!?>*[[P^]G]7;_ +8_[(<6?,_:E_9UB(X._P"-?PW0 'U#^)%
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MBU(CN<GCG@YQS@<5]3_\%@?^2$^ /3_A:VF#\?\ A%_%./ZX/KQG-==\(_\
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ME)QC*I3A5G.$9-247.$5)II-M.T]%%%0=04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %&!DGUZ_A156ZNK:QMY[N[N(K>WMXVFGG
MG=8HH8HU+/)*[$*B(@+,S$*%&20,FFDY-1BG*4FE&*3;DVTDDDFVVVDDDVVT
MDFVDXG.%.,YU)QIPA%SE.<E&,8Q3<I2E)QC&,8IMMM))-MI)LLD;NY YR/7_
M #^M+7$^"_B-X#^(EI>7W@7QCX:\865A=O8WEWX:UK3M<MK6\C/[RUN)M-GN
M(XKA<Y:*1EDVE7V;6!/;5=6C6H3E2KTJM"K&W-3K4ZE*I&Z4ES0J0ISC=--<
MT%=--733>.%Q>%QU"&)P>)P^+H5+\E?#5J5>C/EE*,N2K2G4IRY91E%\LW9Q
M:=FF@HHHK,Z0HHHH .<GGZ#TH.>QQ[]:K7%S;6Z.]Q-%$BJ6<R2! % SDYX
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MI?$K'Z9D6/DI0A)Q4DU>-[2OH]D]'?\ R/7+'QUH&5'VRY .,G[-<#+  #G
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MXKNH+F.RN;'3[N."\&E6$U[/JUUJTT$5O=7T5I9V'VE3>R6OK\*JO0\../\
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MIAL92Q>758MN-*6%DW'%4FE&I0G%2YGRPD^OUVTL:E59U5FZ!B 3CT!P>O\
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M0O7<2, GH2>.>O/X8ZC\E/\ @C__ ,D!\;?]E7U['_A-^%NM<O\ \%*/CO\
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M1:IJ.B%=):9HBT>_;IVL6L;%L1SN\./,D&/=OB__ ,$Q/AY\0=4\*>)_"'Q
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M=WXK_P $[/BYX8^(W[,OP_TG3K^T3Q#\.]'L_ _BG1_-1;K3KW1(?L=C<R0
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MUG5=5(66XUB_CE8O>;%6$)!#;0P6MO!;Q?E&;97PAE5:^7\55L]57&X:6&>
MP&*P7U3 >WC/$5L9+%N">.A0<HT:.$YHJM%SE6C%1B_WC(,]\2N(,*Z>:\!X
M/AJ6'RC&TL4\US'"9A_:&:?4YTL+0P-+"QGR8"IB8QGB*N+:;HR]G&E)WD?
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M*A@.:ICLVIPNH4\-/GJ4<).5UAXUI*K448JK.BYOD_2>(L[\8,'PSEF8</\
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M*1%@<9&#M]#QP" !CKD>H.*[JVT:-,$H<X&/3.,C(ZX/7(&>_:MZ"R"@<8P
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M=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2&44&AO=&]S:&]P(#,N,  X0DE-! 0
M    (7B^A6@X0DE-! 0      #\< 5H  QLE1QP"   "J  < E  "')R,S8P
M,#,R' (% !Y-:6-R;W-O9G0@5V]R9" M($-U<FES(%!R;U-U<#$ .$))300E
M       0X8\G#\@-L<ZNXP]UH$"ALSA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#
MO_XU  (  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              $$   #<          $
M                     0              W    $$
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   $$     4F=H=&QO;F<
M  #<    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   !!     %)G:'1L;VYG    W     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $     CA"24T$#      7
M&@    $   "@    +P   >   %@@   6_@ 8  '_V/_B#%A)0T-?4%)/1DE,
M10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-
M4T94     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M
M$6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
M  )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU
M;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (
M#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC
M*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S
M4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M      !865H@        \U$  0    $6S%A96B
M6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M       DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C
M+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                 &1E<V,
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@                            !D97-C
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0                                  =FEE=P
M    $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M  !7'^=M96%S          $                        "CP    )S:6<@
M     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #<
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M!2PY+&XLHBS7+0PM02T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 !!0$!               ' 0($!08#"/_$ #P1  (! P,"! ,%!0<% 0
M  $" P0%$0 &$@<A$R(Q0111814C<:'P"$*!D<$6,C.QLM'Q%R0F<G/A_]H
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G!'_=_P#SZV]?_=C_ %[OKGK9_BM^/]%U)S?[)_[)_P#'6EUT^O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ? ) # 2(  A$! Q$!_\0
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ML_\ "D/"?BB1M=EMX? FF>,+:>VMX[B]O;:]TK0)(S)-H6F6']O1 8,K ,K
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M*"P%*A1IQRY9="G++(/%_P ?/Q7^'/[1>B?LF?\ !1#]M?XC?#SQMX&^/_\
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(#'#4Z/\ _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
